TempP(3)

TempP(4)

C7728521 2020. Lopinavir/ritonavir: Acute kidney injury following off-label use: 8 case reports.
C7728517 2020. EMA and ICMRA urge continuation of COVID-19 vaccine safety trials.
C7728511 2020. Hydroxychloroquine: Acute intravascular haemolytic anaemia following off-label use: case report.
C7728507 2020. Lopinavir/ritonavir: Sick sinus syndrome following off-label use: case report.
C7728522 2020. PRAC review confirms chloroquine- and hydroxychloroquine-related AEs.
C7728518 2020. Antineoplastics: Various toxicities: 3 case reports.
C7728516 2020. Chloroquine/erythromycin: QT interval prolongation and Torsade de Pointes: case report.
C7728514 2020. Multiple drugs: QT prolongation and elevation of liver function test: case report.
C7728510 2020. Multiple drugs: Invasive pulmonary aspergillosis lack of efficacy and off-label therapy: 4 case reports.
C7728508 2020. Hydroxychloroquine: Electrical storm and QT interval prolongation following off-label use: case report.
C7726305 2020. Gasorelin/prednisolone: COVID-19 infection and weight increase : case report.
C7726302 2020. Dasatinib: COVID-19 pneuminia febrile neutropenia pancytopenia and pleural effusion: case report.
C7726300 2020. Methylprednisolone/tocilizumab: Disseminated strongyloidiasis and off-label use: case report.
C7726283 2020. Lopinavir/ritonavir: Worsening of liver injury following off-label use: 7 case reports.
C7726273 2020. Remdesivir: Intrahepatic cholestasis of pregnancy following compassionate use of remdesivir: case report.
C7726269 2020. Ceftriaxone/hydroxychloroquine/tocilizumab: QT prolongation torsade-de-pointes and off label use: case report.
C7718588 ?. Afflux massif de victimes pédiatriques.
C7718584 2021. Nitric oxide and viral infection: Recent developments in antiviral therapies and platforms.
C7726301 2020. Multiple drugs: Severe acute respiratory syndrome coronavirus 2 infection renal dysfunction and off label use: case report.
C7726299 2020. Azithromycin/hydroxychloroquine: Elevated liver enzymes following off label use: case report.
C7726288 2020. Multiple drugs: COVID-19 and off-label use: 2 case reports.
C7726286 2020. Multiple drugs: COVID-19 acute kidney injury and off label use: 2 case reports.
C7726276 2020. Sarilumab: Thrombocytopenia during an off-label use: case report.
C7726274 2020. Azithromycin/hydroxychloroquine: Prolonged corrected QT following off label use: case report.
C7726270 2020. Multiple drugs: Undetectable IgG and IgM levels and off-label use: case report.
C7714659 2020. XAV-19 de Xenothera candidat traitement anti-Covid-19.
C7700915 2020. Natural bioactive substances for the control of food-borne viruses and contaminants in food.
C7700809 2020. Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences.
C7695440 2020. A review on Promising vaccine development progress for COVID-19 disease.
C7711744 ?. Considerations for the use and study of exogenous surfactant in respiratory disease from COVID-19.
C7705928 ?. Can Hydroxychloroquine Cause G6PD-Related Hemolysis? A Case Study.
C7724756 2020. Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19.
C7709971 2020. SARS?CoV?2: Bioinspired DNase?I?Coated Melanin?Like Nanospheres for Modulation of Infection?Associated NETosis Dysregulation (Adv. Sci. 23/2020).
C7717131 ?. Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic.
33309540 2021. Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast an anti-asthma drug.
33309272 ?. Identification of antiviral antihistamines for COVID-19 repurposing.
C7726715 ?. Phytochemicals against SARS-CoV as potential drug leads.
C7699021 ?. Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on Br J Anaesth 2020; 125: e382?3.
33326798 ?. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
C7728420 ?. Different barriers to nutritional therapy among critically-ill patients with COVID-19.
C7724098 2020. A real?world study of glucocorticoid treatment in COVID?19 patients with different disease severities.
33312453 2021. Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.
33312454 2020. L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies.
33319212 2021. Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19.
33309533 ?. Potential SARS-CoV-2 main protease inhibitors.
33319186 ?. The challenges of distributing COVID-19 vaccinations.
C7723760 ?. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective non-randomized trial.
33313306 2020. Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19.
C7717273 ?. QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.
C7717197 ?. Conflicts over calcium and the treatment of covid-19.
33312125 2020. Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study.
C7714043 ?. Evaluation of potential anti-COVID-19 therapies.
C7713555 2020. A Hydrophobic?Interaction?Based Mechanism Triggers Docking between the SARS?CoV?2 Spike and Angiotensin?Converting Enzyme 2 (Global Challenges 12/2020).
C7716363 2020. Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept single-arm multicenter trial.
C7716359 2020. Complement C5 inhibition in patients with COVID- 19 - a promising target?
33309735 ?. Vitamin D deficiency correlates with a reduced number of natural killer cells in intensive care unit (ICU) and non-ICU patients with COVID-19 pneumonia.
33311985 2020. Reviewing the Effects of Miltefosine and Suggesting It for the Treatment of Coronavirus Disease (COVID-19).
C7709614 ?. Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.
C7705326 2021. Interferon-inducer antivirals: Potential candidates to combat COVID-19.
33309661 2021. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
33310109 ?. Response to ?Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients?.
33310025 ?. Comparison of hospital treatment strategy or of actually received treatment with hydroxychloroquine in COVID-19??.
33309910 ?. Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease.
C7699303 ?. Weight Loss in COVID-19?Positive Nursing Home Residents.
C7720268 2020. A potential hypothesis for 2019-nCoV infection therapy through delivery of recombinant ACE2 by red blood cell-hitchhiking.
33310480 2021. Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.
33312507 ?. Physical activity and COVID-19: an observational and Mendelian randomisation study.
C7720699 2021. Impact of repurposed drugs on the symptomatic COVID-19 patients.
C7719002 ?. Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report.
33312066 2020. Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations.
33333424 2021. Effect of nelfinavir stereoisomers on coronavirus main protease: Molecular docking molecular dynamics simulation and MM/GBSA study.
C7709472 ?. Malnutrition Prolongs the Hospitalization of Patients with COVID-19 Infection: A Clinical Epidemiological Analysis.

C7692431 2020. Enoxaparin-sodium: Lack of efficacy: case report.
C7692423 2020. Hydroxychloroquine: Various toxicities secondary to off label use: 3 case reports.
C7692416 2020. Lopinavir/ritonavir: Bradyarrhythmia following an off-label use : case report.
C7692436 2020. Hydroxychloroquine: Prolonged QTc interval following off-label use: case report.
C7692424 2020. Immunosuppressant: COVID-19 pneumonia: 2 case reports.
C7692421 2020. Azithromycin/hydroxychloroquine: Torsades-de-pointes following off label treatment: case report.
C7692413 2020. Tocilizumab: Lobar pneumonia following off label use: case report.
C7691168 2021. Nature s therapy for COVID-19: Targeting the vital non-structural proteins (NSP) from SARS-CoV-2 with phytochemicals from Indian medicinal plants.
C7685779 2020. An in silico LLPS perturbation approach in the design of a novel SARS-CoV-2 spike receptor-binding domain inhibitor.
C7682129 ?. Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019).
C7677448 2020. Hydroxychloroquine/tocilizumab: Cytomegalovirus enterocolitis and hypovolaemic-shock following off-label use: case report.
C7677439 2020. Drug-drug interactions in patients with COVID-19.
C7677437 2020. Enoxaparin sodium/methylprednisolone: Cytomegalovirus reactivation gastrointestinal haemorrhage and off-label use: case report.
C7677434 2020. Multiple drugs: Neutropenia and COVID-19 infection: 4 case reports.
C7677431 2020. Immunosuppressants: Haematological disorders and COVID-19: 2 case reports.
C7677429 2020. Azithromycin/hydroxychloroquine: Cardiac disorder followed by off-label use: case report.
C7677424 2020. Multiple drugs: Various toxicities and off label use: 3 case reports.
C7677447 2020. Azithromycin/hydroxychloroquine: Torsade-de-pointes following off-label use: case report.
C7677435 2020. Tocilizumab: Decrease in WBC count following an off-label use: case report.
C7677433 2020. Lopinavir/ritonavir/remdesivir: Drug induced liver injury and off label use: 5 case reports.
C7677430 2020. Immunosuppressants: Hepatotoxicity neutropenia and COVID-19 pneumonia : case report.
C7677428 2020. Multiple drugs: Caecal haemorrhagic ulceration cytomegalovirus infection and off-label use: case report.
C7677426 2020. Multiple drugs: Pancytopenia COVID-19 and off-label use: case report.
C7677736 2020. BDA leads call for plasma donations to fight COVID-19.
C7676093 ?. In silico molecular docking and molecular dynamic simulation of potential inhibitors of 3C-like main proteinase (3CLpro) from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) using selected african medicinal plants.
C7652915 2020. Passive Immunisierung mit Rekonvaleszentenplasma bei COVID-19?
C7661830 2020. Multiple drugs: No response: case report.
C7661828 2020. Azithromycin/hydroxychloroquine: Methemoglobinemia following off-label use: case report.
C7661825 2020. Norepinephrine: Lack of efficacy: 3 case reports.
C7661820 2020. Antineoplastics/antiretrovirals: COVID-19 and diarrhoea due to off-label use: 3 case reports.
C7661815 2020. Antivirals/glucocorticoids: Diabetes mellitus and ALT elevation following off-label use in COVID-19: case report.
C7661812 2020. Hydroxychloroquine: Neutropenia maculopapular rash and urinary tract infection following an off label use: 3 case reports.
C7661810 2020. Tocilizumab/unspecified corticosteroids: Spinal epidural abscess: 2 case report.
C7661807 2020. Immunosuppressants: COVID-19-pneumonia: 2 case reports.
C7661831 2020. Candesartan cilexetil: COVID-19 pneumonia: case report.
C7661829 2020. Azithromycin/hydroxychloroquine: Cardiac arrest following off-label use: 2 case reports.
C7661818 2020. Multiple drugs: SARS-CoV-2 infection (COVID-19): 22 case reports.
C7661813 2020. Ascorbic acid: Acute oxalate nephropathy due to off label use: case report.
C7661811 2020. Immune globulin: Lack of efficacy: case report.
C7661803 2020. Lopinavir/ritonavir: Acute liver failure following compassionate use: case report.
C7660967 ?. Why Chinese medicine works for COVID-19.
C7657604 ?. What are the clinical benefits of tocilizumab for COVID-19 patients? Evidence from available case-control studies.
C7649038 ?. Intermetallic Phase Evolution of Cold-Sprayed Ni-Ti Composite Coatings: Influence of As-Sprayed Chemical Composition.
C7648510 2020. Statins in COVID-19: Is there any foundation??.
C7648244 2020. Hydroxychloroquine: QTc prolongation following off-label use: case report.
C7648240 2020. Hydroxychloroquine: QTc-prolongation following an off-label use: case report.
C7648232 2020. Prednisolone/tacrolimus: COVID-19 infection: case report.
C7648225 2020. Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports.
C7648209 2020. Cytarabine/dasatinib/rituximab: Reactivation of COVID-19 pneumonia : case report.
C7648207 2020. Adalimumab/anakinra/dexamethasone: COVID-19 infection cytomegalovirus reactivation and off-label use: case report.
C7648205 2020. Lopinavir/ritonavir/oseltamivir/warfarin interaction: Increase in the INR and alanine aminotransferase following off label use: 10 case reports.
C7648243 2020. Antiviral/immunosuppressant: Various toxicities: case report.
C7648228 2020. Pembrolizumab: Pneumonitis pulmonary cavitation and haemoptysis: case report.
C7648226 2020. Rituximab: Serum sickness: case report.
C7648213 2020. Antithymocyte-globulin: Worsening of SARS-CoV-2 infection: case report.
C7648208 2020. Hydroxychloroquine: Borderline prolongation of QTc interval during off-label treatment: case report.
C7644251 2020. Eficacia y seguridad de la medicina tradicional china en COVID-19: una revisión exploratoria.
C7649658 ?. Tocilizumab in the Management of COVID-19: A Preliminary Report.
C7688272 2020. Bénéfice de l?ivermectine : de la gale ? la COVID-19 un exemple de sérendipité.
C7598544 2020. 153 Do Hydroxychloroquine Disease-Modifying Antirheumatic Agents or Steroids Serve to Prevent COVID-19 Infection?
C7576612 2020. COVID?19 vaccines: the importance of transparency and fact?based education.
C7670260 ?. Plant products in reducing spread of corona virus infection (COVID 19).
33321075 ?. Predicted Cellular Immunity Population Coverage Gaps for SARS-CoV-2 Subunit Vaccines and Their Augmentation by Compact Peptide Sets.
C7670933 2020. P.841QTc changes in the management of SARS-CoV-2 infection in patents schizophrenia spectrum disorders.
C7723026 ?. Nutrition And The Covid-19 Pandemic: Three Factors With High Impact On Community Health.
C7717879 ?. Micronutrients and Bioactive Substances: Their Potential Roles in Combating COVID-19.
C7716744 ?. Increased risk for Covid-19 in patients with Vitamin D deficiency.
33318924 2020. Successful treatment with methyl-prednisolone pulses for the late phase of COVID-19 with respiratory failure: A single-center case series.
33318918 2021. Post-transplant patients with COVID-19 associated acute respiratory distress syndrome a role for Tociluzumab: A case series.
33318764 2020. Brève : Médicaments pour la Covid-19.
C7700096 2020. Infection ? SARS-CoV-2 et biomédicaments : une étude multicentrique fran?"aise de 7808 patients.
33318880 ?. Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2.

C7651988 ?. Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective.
C7604209 2020. TERAPIA COM CÉLULAS-TRONCO EM PACIENTES COM COVID-19: REVISÃO SISTEMÁTICA.
C7604144 2020. PLASMA CONVALESCENTE EM PACIENTES CRÍTICOS COM COVID 19: IMPACTOS DOS ANTICORPOS NEUTRALIZANTES NOS DESFECHOS RESPIRATÓRIOS.
C7604117 2020. CHALLENGES IN THE PRODUCTION OF COVID-19 CONVALESCENT PLASMA ? ANALYSIS OF DONOR RECRUITMENT.
C7604001 2020. MANUTENÇÃO DOS NÍVEIS DE ANTICORPOS NEUTRALIZANTES (NAB) E DE LIGAÇÃO PARA PROTEÍNAS DE NUCLEOCAPSÍDEOS (NP) DE SARS-CoV-2 EM UNIDADES DE PLASMA DE DOADORES CONVALESCENTES (CCP) TRATADOS POR AMOTOSALEN/UVA (A/UVA).
C7603963 2020. PLASMA DE CONVALESCENTES PARA TERAPIA DE COVID-19: RECRUTAMENTO E SELEÇÃO DE DOADORES NO DF.
C7603956 2020. MECANISMOS MOLECULARES DAS RESPOSTAS IMUNOHEMATOLÓGICAS CONTRA O SARS-CV-2 EM PACIENTES COM QUADRO CLÍNICO GRAVE.
C7603942 2020. INDICE DE APROVEITAMENTO DAS BOLSAS DE PLASMA CONVALESCENTE DA COVID-19 NO HEMOCENTRO DE GOIÁS.
C7604225 2020. PLASMA CONVALESCENTE: PERFIL DE DOADORES DURANTE O PERÍODO DE PANDEMIA DA COVID-19.
C7604173 2020. USO DO PLASMA CONVALESCENTE COMO MÉTODO DE TRATAMENTO DA DOENÇA DO CORONAVÍRUS 2019 (COVID-19).
C7604110 2020. CINÉTICA DE ANTICORPOS NEUTRALIZANTES (NAB) E DE LIGAÇÃO CONTRA ANTÍGENOS NUCLEOCAPSÍDEOS (NP) DE SARS-CoV-2 EM DOADORES DE PLASMA CONVALESCENTE (CCP).
C7604108 2020. USO DA AUTO-HEMOTERAPIA EM PACIENTES COM COVID-19: REVISÃO SISTEMÁTICA.
C7604072 2020. COVID-19: RISCOS DA AUTO-HEMOTERAPIA.
C7604067 2020. PRIMEIRAS IMPRESSÕES DA UTILIZAÇÃO DO PLASMA CONVALESCENTE NO TRATAMENTO DA COVID-19 NO ESTADO DO ACRE.
C7604050 2020. USO COMBINADO DE TOCILIZUMABE E CÉLULAS-TRONCO MESENQUIMAIS NO TRATAMENTO DA COVID-19 ? RELATO DE CASO.
C7604006 2020. FATORES PREDITORES DE PERMANÊNCIA EM UTI EM PACIENTES COM COVID-19 TRATADOS COM PLASMA CONVALESCENTE.
C7603977 2020. PERFIL CLÍNICO E LABORATORIAL DOS CANDIDATOS À DOAÇÃO DE PLASMA CONVALESCENTE PARA TRATAMENTO DA COVID-19.
C7603971 2020. QUALIFICAÇÃO DO PLASMA CONVALESCENTE SARS-CoV-2 EM DOADORES DE SANGUE.
C7603964 2020. PERFIL SOROLÓGICO DE CANDIDATOS A DOAÇÃO DE PLASMA CONVALESCENTE PARA COVID-19 DO HEMOCENTRO DE GOIÁS.
C7603955 2020. TRATAMENTO DE COVID-19 COM PLASMA CONVALESCENTE: RELATO DE CASO.
C7654303 ?. HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers.
C7641523 ?. Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?
C7671923 2020. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia.
C7653482 ?. Safety of influenza vaccine during COVID-19.
C7598546 ?. Utility of hypertonic saline and diazepam in COVID-19-related hydroxychloroquine toxicity.
C7677888 2020. Notice of addendum to Article reporting Oxford trial of ChAdOx1 nCoV-19 vaccine.
C7682478 ?. Elevated Rate of HLA Antibodies in Male COVID-19 Convalescent Plasma Donors: A Risk Factor for Transfusion-Related Acute Lung Injury.
C7608061 ?. Micro-Thrombosis Perfusion Defects and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma!
C7608008 ?. In Reply ? Micro-Thrombosis Perfusion Defects and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma!
33308854 ?. Cuestiones por resolver en el tratamiento con glucocorticoides de la infección COVID-19.
C7685948 ?. Tackling the COVID-19 ?cytokine storm? with microRNA mimics directly targeting the 3?UTR of pro-inflammatory mRNAs.
33308935 ?. Combating hypoxemia in COVID-19 patients with a natural oxygen carrier HEMO2Life® (M101).
C7665622 ?. A proposal for clinical trials of COVID-19 treatment using homo-harringtonine.
C7677616 ?. Rational Drug Design and Docking of the RNA Dependent RNA Polymerase Domain of NCoV.
C7677614 ?. Herbal Treatment Approach Towards COVID19.
C7677612 ?. Plasma Therapy Towards COVID Treatment.
C7677613 ?. Identification of potential Vaccine Candidates for COVID19.
C7589470 2020. Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure.
C7662068 2021. Transforming curry extract-spice to liposome-based curcumin: lipocurc to restore and boost brain health in COVID-19 syndrome.
C7680017 ?. Prospectives of algae derived nutraceuticals as supplements for combating COVID-19 and human coronavirus diseases.
33321395 2021. An exploratory study of selenium status in healthy individuals and in patients with COVID-19 in a south Indian population: The case for adequate selenium status.
C7642753 ?. Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan China: a retrospective single-center study with propensity score matching.
C7642754 ?. Effects and Safety of Herbal Medicines among Community-dwelling Residents during COVID-19 Pandemic: A Large Prospective Randomized Controlled Trial (RCT).
C7646037 ?. Severe acute respiratory syndrome?coronavirus?2 spike (S) protein based vaccine candidates: State of the art and future prospects.
C7642756 2021. Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues.
C7603945 ?. Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
33309323 ?. Nucleic Acid-Based Technologies Targeting Coronaviruses.

33258011 2020. Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection.
33303188 2020. Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature.
33304411 2020. A new model for clinical trials to address the COVID-19 emergency.
33299621 2020. Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome.
33301928 2020. Corticosteroids in patients hospitalised for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data.
33304584 2020. Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.
33263622 2020. Potential mouth rinses and nasal sprays that reduce SARS-CoV-2 viral load: What we know so far?
33302163 2020. A molecular docking study of EGCG and theaflavin digallate with the druggable targets of SARS-CoV-2.
33302991 2020. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
33163329 2020. Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review.
33059515 2020. A timely update of global COVID-19 vaccine development.
33168483 2020. Administracion de lopinavir/ritonavir a traves de sonda de nutricion enteral.
32860034 2020. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
33304884 2020. Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease.
33304913 2020. First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia.
33304917 2020. Healthy Dietary Intake Behavior Potentially Modifies the Negative Effect of COVID-19 Lockdown on Depression: A Hospital and Health Center Survey.
33304368 2020. In Search of Herbal Anti-SARS-Cov2 Compounds.
33190937 2020. Tocilizumab como posible causa de colitis isquemica.
33256373 2020. Convalescent plasma for administration of passive antibodies against viral agents.
33289002 2020. Enhancement of the IFN-beta-induced host signature informs repurposed drugs for COVID-19.
33302035 2020. Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective.
33302034 2020. COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.
33239047 2020. Invest in physical activity to protect and promote health: the 2020 WHO guidelines on physical activity and sedentary behaviour.
33255783 2020. A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders.
33298370 2020. Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials.
33307378 2020. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
33304473 2020. COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?
33299899 2020. Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2.
33301818 2020. Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.
33263094 2020. Remdesivir in patients with estimated glomerular filtration rate < 30mL/min/1.73m(2) or on renal replacement therapy.
33303302 2020. Hydrothermotherapy in prevention and treatment of mild to moderate cases of COVID-19.
33298976 2020. Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections.
33293892 2020. Dexamethason.
33233526 2020. Insights in Immuno-Nutrition: Vitamin D as a Potent Immunomodulator.
33299492 2020. BCG Vaccine does not Protect Against COVID-19.
33182382 2020. The Importance of Poly(ethylene glycol) and Lipid Structure in Targeted Gene Delivery to Lymph Nodes by Lipid Nanoparticles.
33264297 2020. Colchicine reduces lung injury in experimental acute respiratory distress syndrome.
33163092 2020. OMS: Covid-19, corticoides mode d'emploi.
33163091 2020. Vaccin Sars-CoV-2 futur : fixer des maintenant une strategie operationnelle.
33163090 2020. Breve : Covid -19 : leflunomide propose pour les patients cancereux.
33173848 2020. Hydroxychloroquine and QT prolongation: reassuring data in approved indications.
33293534 2020. X-ray inactivation of RNA viruses without loss of biological characteristics.
33257204 2020. Convalescent plasma (CP) therapy in patients with COVID-19.

33211457 2012. Remdesivir
33226744 2006. Bamlanivimab
33226742 2006. Casirivimab
33226741 2006. Imdevimab
33200061 2020. Immunotherapeutics for Covid-19 and post vaccination surveillance.
33183004 2020. High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2.
33251412 2020. Chemocentric Informatics Analysis: Dexamethasone Versus Combination Therapy for COVID-19.
33232277 2020. Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities.
33221759 2020. In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues.
33208274 2020. Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia.
33224571 2020. Promising preventive and therapeutic effects of TaibUVID nutritional supplements for COVID-19 pandemic: towards better public prophylaxis and treatment (A retrospective study).
33198951 2020. MMR Vaccination: A Potential Strategy to Reduce Severity and Mortality of COVID-19 Illness.
33234758 2020. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia.
33223658 2020. Neurology and COVID-19: Acting now. Preparing for Future.
33025225 2020. Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study.
33226860 2020. Annals On Call - A Primer on COVID-19 Vaccines.
33226855 2020. Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.
33200031 2020. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.
33222462 2020. Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study.
33229429 2020. Off-target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent.
33202598 2020. The Pivotal Role of Adipocyte-Na K peptide in Reversing Systemic Inflammation in Obesity and COVID-19 in the Development of Heart Failure.
33182802 2020. Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis.
33248195 2020. Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro.
33251389 2020. Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic.
33195828 2020. Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity.
33028485 2020. Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.
33191206 2020. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
33205654 2020. Exploring the Mechanism of Covalent Inhibition: Simulating the Binding Free Energy of alpha-Ketoamide Inhibitors of the Main Protease of SARS-CoV-2.
33238195 2020. Can food and food supplements be deployed in the fight against the COVID 19 pandemic?
33232817 2020. Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19.
33247380 2020. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial.
33236293 2020. The Relation Between Trace Element Status (Zinc, Copper, Magnesium) and Clinical Outcomes in COVID-19 Infection During Pregnancy.
33197762 2020. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes.
33249281 2020. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study.
33254013 2020. Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection.
33197765 2020. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role.
33194191 2020. Can mesenchymal stem cells be used to treat COVID-19-induced pneumonia? (Review).
33030819 2020. Vacunas contra el SARS-CoV-2: inverted question markson una realidad para America Latina?
33037772 2020. Novel use of an old compound? Urologist-led Bacille Calmette-Guerin vaccine trials in the prevention of coronavirus disease 2019.
33119763 2020. Targeting complement activation in COVID-19.
33180920 2020. COVID-19, plasma, and hypogammaglobulinemia.
33181508 2020. Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill Patients with SARS-CoV2 Pneumonia.
33234138 2020. Evidence for treatment with estradiol for women with SARS-CoV-2 infection.
33211246 2020. Can BCG be useful to mitigate the COVID-19 pandemic? A Canadian perspective.
33251029 2020. SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement?
33225317 2020. Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.
33253764 2020. Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update.
33232211 2020. Recombinant vaccines for COVID-19.
33200726 2020. Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials.
33183091 2020. Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: a retrospective cohort study.
33229428 2020. A Valid Warning or Clinical Lore: An Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
33185016 2020. Non-steroidal anti-inflammatory drugs and susceptibility to COVID-19.
33190288 2020. Continuous renal replacement therapy with the addition of CytoSorb((R)) cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series.
33251825 2020. Association Between Yogic Breathing Practice With Perceived Impact of COVID-19: A Cross-Sectional Study From India.
33246381 2020. Complementary Feeding Practices During COVID-19 Outbreak in Daerah Istimewa Yogyakarta, Indonesia, and Its Related Factor.
33232578 2020. The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 In Vitro.
33203214 2020. Polymer microarrays rapidly identify competitive adsorbents of virus-like particles.
33231598 2020. The biomaterial polyphosphate blocks stoichiometric binding of the SARS-CoV-2 S-protein to the cellular ACE2 receptor.
33179788 2020. A review of COVID-19 vaccines and major considerations for diabetic patients.
33104167 2020. SARS-CoV-2 specific T-cells Are Rapidly Expanded for Therapeutic Use and Target Conserved Regions of Membrane Protein.
33202419 2020. How should we use convalescent plasma therapies for COVID-19?
33247004 2020. Covid-19: UK government asks regulator to assess Oxford vaccine as questions are raised over interim data.
33234507 2020. Covid-19: What do we know about the late stage vaccine candidates?
33229332 2020. Covid-19: Oxford vaccine is up to 90% effective, interim analysis indicates.
33229331 2020. Remdesivir for severe covid-19: a clinical practice guideline.
33219049 2020. Covid-19: Pfizer and BioNTech submit vaccine for US authorisation.
33214186 2020. Covid-19: What now for remdesivir?
33199524 2020. Covid-19: Third candidate vaccine will be tested in UK.
33184041 2020. Covid-19: Government's tacit approval of traditional medicine treatments alarms India's doctors.
33249430 2020. Effect of steroids on Covid-19 mortality risk: a Bayesian interpretation.
33244589 2020. How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?
33216852 2020. Immunomodulation as Treatment for Severe COVID-19: a systematic review of current modalities and future directions.
33201228 2020. The misleading "pooled effect estimate" of crude data from observational studies at critical risk of bias: The case of Tocilizumab in COVID-19.
33201178 2020. The impact of tocilizumab on the mortality of patients with COVID-19.
33210302 2020. COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia.
33231155 2020. Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking studies unveils an opportunity against CORONA.
33227451 2020. Innovative trial designs and analyses for vaccine clinical development.
33188930 2020. Causal inference methods for small non-randomized studies: Methods and an application in COVID-19.
33239507 2020. Reversal of the Pathophysiological Responses to Gram-Negative Sepsis by Megadose Vitamin C.
33186137 2020. Coronavirus Disease 2019 Acute Respiratory Failure: Almitrine Drug Resuscitation or Resuscitating Patients by Almitrine?
33106135 2020. Marine Natural Products as A Source of Drug Leads against Respiratory Viruses: Structural and Bioactive Diversity.
33236646 2020. Effects of adjunct treatment with intravenous Octagam on the course of severe COVID-19: results from a retrospective cohort study.
33208076 2020. Addressing the importance of Stem cell-based therapy: a Perspective in the treatment of COVID-19'.
33229949 2021. COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research.
33251593 2020. Review of registered clinical trials for the treatment of COVID-19.
33190277 2020. CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.
33216381 2020. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
33208083 2020. Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country.
33219663 2020. The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'.
33219551 2020. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia.
33246378 2020. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
33187459 2020. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
33183102 2020. Drug repurposing: new strategies for addressing COVID-19 outbreak.
33252992 2020. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications.
33186061 2020. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
33249945 2020. Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study.
33215942 2020. An effective drug against COVID-19: reality or dream?
33183113 2020. Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?
33237840 2020. Genetic and Disability Discrimination During COVID-19.
33211536 2020. Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy.
33243134 2020. COVID-19 Treatment Success After Repeat Courses of Azithromycin: a report of three cases.
33200717 2020. Pharmacological inhibition of MMP3 as a potential therapeutic option for COVID-19 associated acute respiratory distress syndrome.
33231439 2020. Synthesis of Palladium(II) Complexes via Michael Addition: Antiproliferative Effects through ROS-Mediated Mitochondrial Apoptosis and Docking with SARS-CoV-2.
33231925 2020. Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial.
33236142 2020. Zinc and SARSCoV2: A molecular modeling study of Zn interactions with RNAdependent RNApolymerase and 3Clike proteinase enzymes.
33241872 2020. Tocilizumab administration is associated with reduction in biomarkers of coronavirus disease 2019 (COVID-19) infection.
33215721 2020. Ketamine in COVID-19 patients: Thinking out of the box.
33200828 2020. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.
33188401 2020. Vitamin D Deficiency Is Inversely Associated with COVID-19 Incidence and Disease Severity in Chinese People.
33249050 2020. Aerosol inhalation delivery of triazavirin in mice: outlooks for advanced therapy against novel viral infections.
33190493 2020. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
33226815 2020. Theoretical Design of Functionalized Gold Nanoparticles as Antiviral Agents against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

33160408 2020. Risk of pre-term births and major birth defects resulting from paternal intake of COVID-19 medications prior to conception.
33235975 2020. COVID-19 mortality increases with northerly latitude after adjustment for age suggesting a link with ultraviolet and vitamin D.
33235974 2020. Zinc as nutritional intervention and prevention measure for COVID-19 disease.
33235973 2020. Dietary micronutrients in the wake of COVID-19: an appraisal of evidence with a focus on high-risk groups and preventative healthcare.
33230498 2020. COVID-19: is there a role for immunonutrition, particularly in the over 65s?
33230497 2020. Nutrition, immunity and COVID-19.
33230496 2020. Avoidance of vitamin D deficiency to slow the COVID-19 pandemic.
33191263 2020. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
33178445 2020. Risk/caution of vitamin D insufficiency for quarantined athletes returning to play after COVID-19.
33064679 2020. SARS-CoV-2: coronavirus previos, respuesta inmune y desarrollo de vacunas.
33247247 2020. Donating convalescent plasma for COVID-19 patients.
33190859 2020. Dexmedetomidine: another arrow in the quiver to fight COVID-19 in intensive care units.
33187329 2020. Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.
33230386 2020. Molecular targets and system biology approaches for drug repurposing against SARS-CoV-2.
33223560 2020. An in-silico study on selected organosulfur compounds as potential drugs for SARS-CoV-2 infection via binding multiple drug targets.
33189639 2020. Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises.
33229384 2020. Dexamethasone or hydrocortisone in COVID-19?
33219050 2020. Interferon therapy for COVID-19 and emerging infections: Prospects and concerns.
33230415 2020. Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series.
33189888 2020. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.
32337537 2020. Access to Coronavirus Disease 2019 Clinical Trials by English and Non-English Speakers Is Needed.
33199348 2020. Vitamin D deficiency and COVID-19.
33187772 2020. Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital.
33183578 2020. Copper as a potential adjunct therapy for critically ill COVID-19 patients.
33183539 2020. Prevalence and severity of malnutrition in hospitalized COVID-19 patients.
33183522 2020. Prevalence of obesity and hypovitaminosis D in elderly with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
33229356 2020. Efficacite et innocuite des agents antiviraux contre le SRAS-CoV-2, selon des donnees d'etudes sur la COVID-19 et d'autres infections virales aigues : revue systematique et meta-analyse.
33229354 2020. Efficacite et innocuite du plasma de convalescent en cas de forme grave de COVID-19, extrapolee de donnees relatives a d'autres formes graves d'infections respiratoires virales : revue systematique et meta-analyse.
33230174 2020. Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions.
33190011 2020. Culinary spice bioactives as potential therapeutics against SARS-CoV-2: Computational investigation.
33200026 2020. Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor.
33043164 2020. A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan.
33205613 2020. Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions.
33225308 2020. Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation.
33225307 2020. A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019.
33225306 2020. Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019.
33225304 2020. Rescue Treatment With High-Dose Gaseous Nitric Oxide in Spontaneously Breathing Patients With Severe Coronavirus Disease 2019.
33240723 2020. Cardiac Adverse Events With Remdesivir in COVID-19 Infection.
33194485 2020. Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients.
33197212 2020. The treatment of SARS-CoV2 with Antivirals and Mitigation of the Cytokine Storm Syndrome: the role of gene expression.
33248420 2020. Case report: Nutrition therapy and side-effects monitoring in critically ill coronavirus disease 2019 patients.
33251371 2020. Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19.
33230487 2020. Protein-ligand binding interactions of imidazolium salts with SARS CoV-2.
33225084 2020. Designing spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics.
33253762 2020. Gamma-oryzanol as a potential modulator of oxidative stress and inflammation via PPAR-y in adipose tissue: a hypothetical therapeutic for cytokine storm in COVID-19?
33135597 2020. No significant association between vitamin D and COVID-19. A retrospective study from a northern Italian hospital.
33251800 2020. A Novel Angiotensin Converting Enzyme 2 (ACE2) Activating Peptide: A Reflection of 10 Years of Research on a Small Peptide Ile-Arg-Trp (IRW).
33252246 2020. The Effects of Traditional Chinese Medicine as an Auxiliary Treatment for COVID-19: A Systematic Review and Meta-analysis.
33251541 2020. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
33221868 2020. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
33219675 2020. Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers.
33247644 2020. Pancreatic Injury in COVID-19 Patients.
33215965 2020. An innovative method for the selection of inhibitors of the viral spike-glycoprotein of the SARS-CoV.
33252031 2020. Identification of naphthyridine and quinoline derivatives as potential Nsp16-Nsp10 inhibitors: a pharmacoinformatics study.
33252008 2020. Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach.
33251983 2020. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
33251975 2020. Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19.
33251972 2020. Evaluation of traditional ayurvedic Kadha for prevention and management of the novel Coronavirus (SARS-CoV-2) using in silico approach.
33251965 2020. Nitric oxide boosters as defensive agents against COVID-19 infection: an opinion.
33251943 2020. Computational guided identification of novel potent inhibitors of N-terminal domain of nucleocapsid protein of severe acute respiratory syndrome coronavirus 2.
33246398 2020. Exploring nature's bounty: identification of Withania somnifera as a promising source of therapeutic agents against COVID-19 by virtual screening and in silico evaluation.
33246394 2020. Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein.
33228481 2020. Molecular dynamics simulation perception study of the binding affinity performance for main protease of SARS-CoV-2.
33228475 2020. Computational gene expression profiling in the exploration of biomarkers, non-coding functional RNAs and drug perturbagens for COVID-19.
33226303 2020. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
33225870 2020. In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be effective against novel Coronavirus disease (COVID-19).
33225826 2020. Cordycepin: a bioactive metabolite of Cordyceps militaris and polyadenylation inhibitor with therapeutic potential against COVID-19.
33213294 2020. Virtual screening and molecular simulation study of natural products database for lead identification of novel coronavirus main protease inhibitors.
33200680 2020. In silico screening and molecular dynamics of phytochemicals from Indian cuisine against SARS-CoV-2 M(Pro).
33186212 2020. Highlight of SARS-CoV-2 Vaccine Development against COVID-19 Pandemic.
33217030 2020. Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review.
33210826 2020. The potential effects of clinical antidiabetic agents on SARS-CoV-2.
33210953 2020. Potential inhibitors of SARS-CoV-2: recent advances.
33025599 2020. Integrated network pharmacology and molecular docking strategy to explore the mechanism of medicinal and edible Astragali Radix-Atractylodis Macrocephalae Rhizoma acting on pneumonia via immunomodulation.
33252679 2020. Lessons from BCG for SARS-CoV-2 vaccine candidates.
33216906 2020. The effect of IL-6 inhibitors on mortality among hospitalized COVID-19 patients: a multicenter study.
33234007 2020. Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19.
33107999 2020. On the relationship between BCG coverage and national Covid-19 outcome: could "heterologous" herd immunity explain why some countries are better off?
33222314 2020. PCSK9 inhibitors for COVID-19: An opportunity to enhance the antiviral action of interferon in patients with hypercholesterolemia.
33230947 2020. Thromboinflammation in COVID-19: Can alpha2 -Macroglobulin Help to Control the Fire?
33219167 2020. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
33231648 2020. Study Aims to Identify Drugs That Could Be Repurposed for COVID-19.
33248473 2020. The place for remdesivir in COVID-19 treatment.
33217363 2020. Expecting the unexpected with COVID-19 vaccines.
33217362 2020. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
33248469 2020. Corticosteroids for COVID-19: the search for an optimum duration of therapy.
33189161 2020. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.
33189160 2020. Nebulised interferon beta-1a for patients with COVID-19.
33210607 2020. Is Tirschenreuth the Colorado of Germany linking high COVID-19 mortality and low magnesium in drinking water?
33174617 2020. Optimizing clinical research procedures in public health emergencies.
33234101 2020. Recent Approaches of Repositioning and Traditional Drugs for the Treatment of COVID-19 Pandemic Outbreak.
33208074 2020. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV-2 Infection (COVID-19).
33185159 2020. Drug Re-purposing Approach and Potential Therapeutic Strategies to Treat COVID-19.
33232588 2020. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
33210858 2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
33207102 2020. Audio Interview: Covid-19 in Europe and New Information on Vaccines.
33176090 2020. Audio Interview: An Update from Operation Warp Speed.
33252301 2020. Nanomedicinal delivery of stimulator of interferon genes agonists: recent advances in virus vaccination.
33239758 2020. COVID-19 vaccines poised for launch, but impact on pandemic unclear.
33230343 2020. Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
33230340 2020. Will patient-centric sampling become the norm for clinical trials after COVID-19?
33230278 2020. Why Oxford's positive COVID vaccine results are puzzling scientists.
33236418 2020. HMGB1: A pleiotropic activity.
33203811 2020. Potential SARS-CoV-2 protease Mpro inhibitors: Repurposing FDA-approved drugs.
33191068 2020. Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen Granules against coronavirus disease 2019 pneumonia.
33222316 2020. Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured Vero cells.
33210447 2020. Potential of algal metabolites for the development of broad-spectrum antiviral therapeutics: Possible implications in COVID-19 therapy.
33200839 2020. An approach of fatty acids and resveratrol in the prevention of COVID-19 severity.
33245005 2020. JAK-STAT pathway inhibition and their implications in COVID-19 therapy.
33184146 2020. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study).
33184179 2020. Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients.
33184171 2020. Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention.

33210457 2020. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
33185582 2020. COVID-19 in age-related neurodegenerative diseases: is there a role for vitamin D3 as a possible therapeutic strategy?
33234268 2020. Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents.
33221129 2020. Magnesium and inflammation: Advances and perspectives.
33208020 2020. CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target.
33215959 2020. Drug Discovery Targeting COVID-19.
33230045 2020. Plasma Concentrations and Safety of Lopinavir/ritonavir in COVID-19 Patients A Short Communication.
33231325 2020. A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations.
33189582 2020. Ivermectin: An Anthelmintic, an Insecticide, and Much More.

33217576 2020. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study.
33212256 2020. Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.
33233817 2020. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
33203141 2020. The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.
33249142 2020. Low dose radiotherapy in the management of covid19 pneumonia (LOWRAD-Cov19). Preliminary report.
33211088 2021. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.
33199981 2020. The potential antiviral effect of major royal jelly protein2 and its isoform X1 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Insight on their sialidase activity and molecular docking.
33245459 2020. Molecular docking and simulation investigation: effect of beta-sesquiphellandrene with ionic integration on SARS-CoV2 and SFTS viruses.
33219091 2020. Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management.
33220384 2020. Glucocorticoid benefits the ventilatory function of severe/critical COVID-19 patients.
33250604 2021. DFT and molecular docking study of chloroquine derivatives as antiviral to coronavirus COVID-19.
33223766 2021. Molecular interaction analysis of Sulawesi propolis compounds with SARS-CoV-2 main protease as preliminary study for COVID-19 drug discovery.
33186044 2020. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
33203821 2020. Repurposing screens of FDA-approved drugs identify 29 inhibitors of SARS-CoV-2.
33199930 2020. A computational study to disclose potential drugs and vaccine ensemble for COVID-19 conundrum.
33200284 2020. Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity.
33071352 2020. Anti-COVID-19 terpenoid from marine sources: a docking, ADMET and molecular dynamics study.
33223566 2020. Synthesis of potentially new Schiff bases of N-substituted-2-quinolonylacetohydrazides as anti-Covid-19.
33227231 2020. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis.
33248057 2020. Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective.
33242452 2020. The Science is There: Key Considerations for Stabilizing Viral Vector-Based Covid-19 Vaccines.
33212162 2020. Warp-Speed Covid-19 Vaccine Development: Beneficiaries of Maturation in Biopharmaceutical Technologies and Public-Private Partnerships.
33221625 2020. The bioenergetics of COVID-19 immunopathology and the therapeutic potential of biophysical radiances.
33200935 2020. Computational Design of 25-mer Peptide Binders of SARS-CoV-2.
33052685 2020. Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase.
33232798 2020. Coronavirus pandemic: is H2O2 mouthwash going to overcome the chlorhexidine in dental practices?
33209439 2020. Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review.
33218357 2020. The dark side of the spoon - glucose, ketones and COVID-19: a possible role for ketogenic diet?
33251385 2020. RNA Vaccines for COVID-19: Five Things Every Cardiologist Should Know.
33220855 2020. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
33220853 2020. Age and frailty in COVID-19 vaccine development.
33160456 2020. What could fair allocation of an efficacious COVID-19 vaccine look like in South Africa?
33241526 2020. Photobiomodulation therapy as a high potential treatment modality for COVID-19.
33234678 2021. Inhibiting the reproduction of SARS-CoV-2 through perturbations in human lung cell metabolic network.
33246693 2020. Does Yadgir population have copper-mediated intrinsic immunity to resist COVID-19 challenge?
33213999 2020. Cyclin dependent kinase inhibitors as a new potential therapeutic option in management of COVID-19.
33246694 2020. Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19?
33246691 2020. Zinc supplementation for males during COVID-19: Is it beneficial?
33239231 2020. Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.
33214002 2020. Is there an underlying link between COVID-19, ACE2, oxytocin and vitamin D?
33245278 2020. The paradoxical effect of IL-6 and implications for the use of Tocilizumab in Covid-19 patients.
33059225 2020. Is a COVID-19 vaccine developed by nature already at work?
33219182 2020. Systematic review on current antiviral therapy in COVID-19 pandemic.
33235105 2020. First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.
33224734 2021. Therapeutic potential of miRNAs targeting SARS-CoV-2 host cell receptor ACE2.
33205039 2020. The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19.
33243230 2020. Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19.
33200379 2020. Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization.
33236176 2020. Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease.
33201386 2020. Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2.
33066442 2020. The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials.
33207753 2020. Mini-Review on the Roles of Vitamin C, Vitamin D, and Selenium in the Immune System against COVID-19.
33202656 2020. Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.
33233748 2020. Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?
33247210 2020. Nanomedicine and the COVID-19 vaccines.
33204428 2020. Use of convalescent plasma therapy in Eight mild COVID-19 patients.
33204427 2020. Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers.
33251388 2020. High affinity of host human microRNAs to SARS-CoV-2 genome: An in silico analysis.
33208167 2020. Garlic (Allium sativum L.): a potential unique therapeutic food rich in organosulfur and flavonoid compounds to fight with COVID-19.
33202670 2020. Vitamin D3 as Potential Treatment Adjuncts for COVID-19.
33245731 2020. MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection.
33235888 2020. Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.
33204764 2020. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19.
33204763 2020. Bringing New Meaning to the Term "Adaptive Trial": Challenges of Conducting Clinical Research During the Coronavirus Disease 2019 Pandemic and Implications for Implementation Science.
33204761 2020. Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19.
33204749 2020. Occult Colonic Perforation in a Patient With Coronavirus Disease 2019 After Interleukin-6 Receptor Antagonist Therapy.
33183501 2020. Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report.
33221457 2021. Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis.
33206688 2020. EGYVIR: An immunomodulatory herbal extract with potent antiviral activity against SARS-CoV-2.
33231938 2020. Is remdesivir important in clinical practice as a treatment against COVID19? A study based on metaanalysis data.
33226581 2020. Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can Play a Preventive Role Against Viral Diseases Including COVID-19.
33203671 2020. Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions?
33210243 2020. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction.
33248226 2020. Improved production of SARS-CoV-2 spike receptor-binding domain (RBD) for serology assays.
33242734 2020. COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib.
33212437 2020. Intravenous Immunoglobulin for the Treatment of COVID-19: A Promising Tool.
33227067 2020. Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19.
33211436 2020. La corticotherapie chez le patient critique atteint d'une pneumopathie interstitielle a SARS-CoV-2.
33239928 2020. Effect of Pandemic-Related Confinement on Vitamin D Status Among Children Aged 0-6 Years in Guangzhou, China: A Cross-Sectional Study.
33116980 2020. Current Options in the Treatment of COVID-19: A Review.
33240503 2020. Electrical storm in a patient with COVID-19 treated with hydroxychloroquine: A case report.
33199969 2020. Synthesis of novel coumarin analogues: Investigation of molecular docking interaction of SARS-CoV-2 proteins with natural and synthetic coumarin analogues and their pharmacokinetics studies.
33204210 2020. Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety.
33199968 2020. Status of the Current COVID-19 Vaccine Candidates: Implications in the Saudi Population.
33239694 2020. In silico studies evidenced the role of structurally diverse plant secondary metabolites in reducing SARS-CoV-2 pathogenesis.
33235258 2020. Identification and validation of 174 COVID-19 vaccine candidate epitopes reveals low performance of common epitope prediction tools.
33230180 2020. Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis.
33214648 2020. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers.
33208827 2020. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19.
33203926 2020. High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents.
33247109 2020. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
33235253 2020. Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19.
33235189 2020. Battle at the entrance gate: CIITA as a weapon to prevent the internalization of SARS-CoV-2 and Ebola viruses.
33235188 2020. The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro.
33203839 2020. GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro.
33242791 2020. A safety consideration of mesenchymal stem cell therapy on COVID-19.
33237619 2020. Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID-19-associated organ failure.
33218366 2020. Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project).
33230349 2020. Advances in Developing Small Molecule SARS 3CL(pro) Inhibitors as Potential Remedy for Corona Virus Infection.
33198605 2020. Therapeutic potential of inhalable medications to combat coronavirus disease-2019.
33229187 2020. Sex and COVID-19: A Protective Role for Reproductive Steroids.
33244947 2020. Tocilizumab and COVID-19: A Meta-Analysis of 2120 Patients with Severe Disease and Implications for Clinical Trial Methodologies.
33237663 2020. Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey.
33217916 2020. COVID-19 Infection Detection and Prevention by SARS-CoV-2 Active Antigens: A Synthetic Vaccine Approach.
33202961 2020. Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.
33243253 2020. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.
33249060 2020. The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines.
33232783 2020. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19.
33200085 2020. Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters.
33200084 2020. Structure-guided discovery approach identifies potential lead compounds targeting M(pro) of SARS-CoV-2.
33218024 2020. Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model.
33218001 2020. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.

33097846 2020. The race to make COVID antibody therapies cheaper and more potent.
33069206 2020. Antiviral essential oils incorporated in nanocarriers: strategy for prevention from COVID-19 and future infectious pandemics.
33139569 2020. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.

33064991 2020. Timeline: Vaccines.
33160446 2020. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
33137690 2020. Interaction of small molecules with the SARS-CoV-2 main protease in silico and in vitro validation of potential lead compounds using an enzyme-linked immunosorbent assay.
33126128 2020. In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor.
33131530 2020. Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19.
33074111 2020. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
33065388 2020. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
33046113 2020. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study.
33172477 2020. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis.
33159417 2020. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
33179852 2020. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection.
33130275 2020. COVID-19 and antimalarials. Have we been doing it wrong all along?
33130280 2020. Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.
33130279 2020. In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain.
33190802 2020. Recent progress of antiviral therapy for coronavirus disease 2019.
33131721 2020. Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M(pro), using molecular docking and dynamics simulation studies.
33098835 2020. Translating bioactive peptides for COVID-19 therapy.
33069672 2020. ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors.
33068588 2020. Perspectives on mechanistic implications of ROS inducers for targeting viral infections.
33065096 2020. Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2.
33065092 2020. Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic.
33160938 2020. Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.
33193454 2020. CoVaccine HT Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization.
33193448 2020. Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.
33193427 2020. Tea Bioactive Modulate Innate Immunity: In Perception to COVID-19 Pandemic.
33193385 2020. Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology.
33163000 2020. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
33133090 2020. Targeting Lipid Rafts-A Potential Therapy for COVID-19.
33133071 2020. Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial.
33123165 2020. Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.
33117404 2020. As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention.
33117391 2020. An Effective COVID-19 Vaccine Needs to Engage T Cells.
33117359 2020. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19.
33101309 2020. Emerging Concepts and Technologies in Vaccine Development.
33101291 2020. Perspective: The Potential Effects of Naringenin in COVID-19.
33072130 2020. Cell-Free Therapies: Novel Approaches for COVID-19.
33072111 2020. Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment.
33072093 2020. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
33042151 2020. Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective.
33093657 2020. Self-amplifying RNA vaccines for infectious diseases.
33184504 2020. Molecular targeting of vulnerable RNA sequences in SARS CoV-2: identifying clinical feasibility.
33189776 2020. Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19.
33161002 2020. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.
33161557 2020. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview.
33062618 2020. Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine.
33184600 2020. Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2.
33083517 2020. Leaving no stone unturned: Allosteric targeting of SARS-CoV-2 spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain.
33028776 2020. Implications for White Matter Vulnerability to Anti-interleukin-6 Receptor Antibody Treatment.
32999229 2020. Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course.
32963155 2020. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
33191372 2020. A Favipiravir-induced Fever in a Patient with COVID-19.
32980157 2020. Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19.
33068560 2020. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon.
33094705 2020. Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2.
33094701 2020. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study.
33094680 2020. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
33089730 2020. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19.
33089728 2020. Prevention of SARS-CoV-2 cell entry: insight from in silico interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2.
33084512 2020. Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations.
33073716 2020. A computational and bioinformatic analysis of ACE2: an elucidation of its dual role in COVID-19 pathology and finding its associated partners as potential therapeutic targets.
33073712 2020. Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds.
33073699 2020. Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection.
33155531 2020. Identification and characterization of novel RdRp and Nsp15 inhibitors for SARS-COV2 using computational approach.
33155524 2020. Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines, designed by reverse epitomics approach, show potential to cover large ethnically distributed human population worldwide.
33150860 2020. Traditional medicinal plants against replication, maturation and transmission targets of SARS-CoV-2: computational investigation.
33150855 2020. SARS-CoV-2 M(pro) inhibitors: identification of anti-SARS-CoV-2 M(pro) compounds from FDA approved drugs.
33146070 2020. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
33143552 2020. Identification of natural inhibitors against Mpro of SARS-CoV-2 by molecular docking, molecular dynamics simulation, and MM/PBSA methods.
33140706 2020. Targeting the initiation and termination codons of SARS-CoV-2 spike protein as possible therapy against COVID-19: the role of novel harpagide 5-O-beta-D-glucopyranoside from Clerodendrum volubile P Beauv. (Labiatae).
33140703 2020. Targeting SARS-CoV-2 nucleocapsid oligomerization: Insights from molecular docking and molecular dynamics simulations.
33140695 2020. Computer aided identification of potential SARS CoV-2 main protease inhibitors from diterpenoids and biflavonoids of Torreya nucifera leaves.
33138699 2020. Emerging of composition variations of SARS-CoV-2 spike protein and human ACE2 contribute to the level of infection: in silico approaches.
33131430 2020. An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin alpha.
33141117 2020. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome.
33168277 2020. Successful treatment of a critical COVID-19 patient with tocilizumab.
33072190 2020. Systematic analyses on the potential immune and anti-inflammatory mechanisms of Shufeng Jiedu Capsule against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-caused pneumonia.
33034095 2020. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
33080692 2020. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: A case report.
33036293 2020. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M(pro)).
33142770 2020. In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2.
33138197 2020. Antiviral and Immunomodulatory Effects of Phytochemicals from Honey against COVID-19: Potential Mechanisms of Action and Future Directions.
33137894 2020. Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies.
33105830 2020. Probiotics in Treatment of Viral Respiratory Infections and Neuroinflammatory Disorders.
33066278 2020. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor.
33053830 2020. Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein-Human ACE2 Receptor Interface.
33050360 2020. Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study.
33172092 2020. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M(pro) Protease.
33147850 2020. Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation.
33147821 2020. Epitope-Based Immunoinformatics Approach on Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus-2.
33053279 2020. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
33031652 2020. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
33072338 2020. Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach.
33181320 2020. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study.
33044019 2020. Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.
33163253 2020. Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode.
33033405 2020. Preemptive interleukin-6 blockade in patients with COVID-19.
33110184 2020. Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses.
33060704 2020. Statin use is associated with lower disease severity in COVID-19 infection.
33051534 2020. Lack of tocilizumab effect on mortality in COVID19 patients.
33051517 2020. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.
33046764 2020. Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.
33154498 2020. Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
33154452 2020. Impact of tocilizumab administration on mortality in severe COVID-19.
33154404 2020. Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach.
33051445 2020. A systematic review of SARS-CoV-2 vaccine candidates.
33040075 2020. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment.
33144565 2020. Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19.
33144557 2020. Outsmarting SARS-CoV-2 by empowering a decoy ACE2.
33188163 2020. Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner.
33097846 2020. The race to make COVID antibody therapies cheaper and more potent.
33069206 2020. Antiviral essential oils incorporated in nanocarriers: strategy for prevention from COVID-19 and future infectious pandemics.
33139569 2020. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.

33078827 2020. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.
33147623 2020. A review on drug repurposing applicable to COVID-19.
33147627 2020. Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research.
33061304 2020. Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19.
33116043 2020. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome?
33116037 2020. Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?
33127568 2020. Union is strength: antiviral and anti-inflammatory drugs for COVID-19.
33124007 2020. Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment.
33176367 2020. Favipiravir and COVID-19: A Simplified Summary.
33161277 2020. COVID-19 update: The race to therapeutic development.
33132205 2020. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
33095409 2020. Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.
33078372 2020. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
33068263 2020. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
33084001 2020. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
33139967 2020. Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries.
33152333 2020. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead.
33137330 2020. Functional and druggability analysis of the SARS-CoV-2 proteome.
33117994 2020. What Stone-formers Should Know About Vitamin C and D Supplementation in the COVID-19 Era.
33069187 2020. Transfer Factor as an Option for Managing the COVID-19 Pandemic.
33092925 2020. Identification of tuna protein-derived peptides as potent SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation.
33041708 2020. The Functional Medicine Approach to COVID-19: Nutrition and Lifestyle Practices for Strengthening Host Defense.
33041706 2020. The Functional Medicine Approach to COVID-19: Virus-Specific Nutraceutical and Botanical Agents.
33099620 2020. Treating COVID-19: are we missing out the window of opportunity?
33152616 2021. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
33069124 2021. MEDT study of the 1,3-DC reaction of diazomethane with Psilostachyin and investigation about the interactions of some pyrazoline derivatives with protease (M(pro)) of nCoV-2.
33173250 2020. Towards a novel peptide vaccine for Middle East respiratory syndrome coronavirus and its possible use against pandemic COVID-19.
33041407 2020. Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach.
33184722 2020. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
33041371 2020. Screening of potential drug from Azadiractha Indica (Neem) extracts for SARS-CoV-2: An insight from molecular docking and MD-simulation studies.
33100380 2020. Identification of alkaloids from Justicia adhatoda as potent SARS CoV-2 main protease inhibitors: An in silico perspective.
33100379 2020. DFT Investigation of Atazanavir as Potential Inhibitor for 2019-nCoV Coronavirus M protease.
33100378 2020. Synthesis, anti-bacterial evaluation, DFT study and molecular docking as a potential 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 inhibitors of a novel Schiff bases.
33162722 2020. A comprehensive overview of proteomics approach for COVID 19: new perspectives in target therapy strategies.
33119313 2020. Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches.
33095583 2020. Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses.
33090793 2020. Targeting Proteases for Treating COVID-19.
33169644 2020. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.
33090972 2020. Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models.
32971043 2020. Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.
33032171 2020. Hypothesis: Oxytocin is a direct COVID-19 antiviral.
33069843 2020. Antivirals in the time of COVID-19 - not as easy as it looks!
33052325 2020. Spike protein-based epitopes predicted against SARS-CoV-2 through literature mining.
33049737 2020. Pentoxifylline, a drug with antiviral, anti-inflammatory and bronchodilatory effects may be a possible drug candidate for SARS-CoV-2.
33142828 2020. Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity.
33121019 2020. The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19.
33105731 2020. A Review of Nutrition Support Guidelines for Individuals with or Recovering from COVID-19 in the Community.
33092041 2020. The Role of Micronutrients in Support of the Immune Response against Viral Infections.
33147894 2020. Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study.
33049573 2020. Pharmaconutrition revisited for critically ill patients with coronavirus disease 2019 (COVID-19): Does selenium have a place?
33062414 2020. Computational perspectives revealed prospective vaccine candidates from five structural proteins of novel SARS corona virus 2019 (SARS-CoV-2).
33033705 2020. Prerequisite of doing clinical trial with drugs in COVID-19 patients: Situational experience.
33033700 2020. Challenges and opportunities for sponsors in conducting clinical trials during a pandemic.
33033699 2020. Addressing challenges due to the COVID-19 pandemic - A site and investigator perspective.
33033698 2020. COVID-19 effect on clinical research: Single-site risk management experience.
33031856 2020. Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?
33167571 2020. Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.
33122936 2020. Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.
33116761 2020. Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease.
33072896 2020. An efficient planning technique for low dose whole lung radiation therapy for covid-19 pandemic patients.
33035549 2020. Use of protease inhibitors for the prevention of COVID-19.
33037151 2020. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
33028676 2020. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases.
33093202 2020. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
33031994 2020. Omega-3 fatty acids in the psychological and physiological resilience against COVID-19.
33147503 2020. Host sphingolipids: Perspective immune adjuvant for controlling SARS-CoV-2 infection for managing COVID-19 disease.
33034824 2020. Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19.
33185784 2020. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
33110944 2020. A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.
33064571 2020. Review of COVID-19 Antibody Therapies.
33122172 2020. Repurposing Nucleoside Analogs for Human Coronaviruses.
33122171 2020. Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase.
33139290 2020. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
33113325 2020. Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris(R)) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series.
33169132 2020. Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets.
33054436 2020. Chemical composition and pharmacological mechanism of Shenfu decoction in the treatment of novel coronavirus Pneumonia (COVID-19).
33170521 2020. Step toward repurposing drug discovery for COVID-19 therapeutics through in silico approach.
33128525 2020. Herbal approach for the management of C0VID-19: an overview.
33161757 2020. A comprehensive review on sarilumab in COVID-19.
33094669 2020. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.
33151781 2020. An overview on the use of antivirals for the treatment of patients with COVID19 disease.
33121319 2020. SARS-CoV-2 vaccine candidates in rapid development.
33079613 2020. Tocilizumab prescribing criteria for COVID-19 patients.
33079612 2020. The Missing Link in the Covid-19 Vaccine Race.
33064630 2020. Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic.
33175614 2020. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
33175602 2020. Impact of COVID-19 on women and children and the need for a gendered approach in vaccine development.
33155997 2020. Possible role of Unani Pharmacology in COVID-19 - a narrative review.

33119257 2020. Profiling SARS-CoV-2 Main Protease (M(PRO)) Binding to Repurposed Drugs Using Molecular Dynamics Simulations in Classical and Neural Network-Trained Force Fields.
33112126 2020. Targeting Crucial Host Factors of SARS-CoV-2.
33052254 2020. Why PB28 Could Be a Covid 2019 Game Changer?
33034449 2020. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.
33134697 2020. Quantitative Structure-Activity Relationship Machine Learning Models and their Applications for Identifying Viral 3CLpro- and RdRp-Targeting Compounds as Potential Therapeutics for COVID-19 and Related Viral Infections.
33062955 2020. Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection.
33062954 2020. Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?
33062953 2020. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
33062952 2020. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
33062951 2020. SARS-CoV-2 Vaccine Development: An Overview and Perspectives.
33062950 2020. Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections.
33062949 2020. Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19.
33100351 2020. Dinitrosyl Iron Complexes with Thiol-Containing Ligands Can Suppress Viral Infections as Donors of the Nitrosonium Cation (Hypothesis).
33063092 2020. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
33146673 2020. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.
33098645 2020. QTc interval prolongation and life-threatening arrhythmias during hospitalization in patients with COVID-19. Results from a multi-center prospective registry.
33036639 2020. Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.
33023646 2020. Anakinra: a silver lining in COVID-19?
33023627 2020. TPE seems to be a treatment that may improve outcomes by effectively removing fibrin degradation products and restoring coagulation status: fact or fiction?
33121512 2020. Corticosteroids in severe COVID-19: a critical view of the evidence.
33134951 2020. Resolution of Coronavirus Disease 2019 Infection and Pulmonary Pathology With Nebulized DAS181: A Pilot Study.
33134949 2020. Evaluation of the Efficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients With Coronavirus Disease 2019.
33134941 2020. Anticytokine Therapies in Severe Coronavirus Disease 2019 Should Be Informed by Detailed Inflammatory Profiling and Specific Therapeutic Targets.
33063037 2020. Convalescent Plasma Therapy in Four Critically Ill Pediatric Patients With Coronavirus Disease 2019: A Case Series.
33063035 2020. Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients.
33042702 2020. The Possibility and Cause of Relapse After Previously Recovering From COVID-19: A Systematic Review.
33123427 2020. A Snapshot of the Response from UK-based Clinical Trials of Investigational Medicinal Products to COVID-19.
33101806 2020. Subcutaneous Emphysema in Patients With COVID-19 Infection: A Report of Three Cases.
33033686 2020. Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection.
33101792 2020. Bioethical Implications in Vaccine Development, a COVID-19 Challenge.
33062500 2020. Ivermectin: A Closer Look at a Potential Remedy.
33178522 2020. Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.
33069048 2020. The use of copper to help prevent transmission of SARS-coronavirus and influenza viruses. A general review.
33111813 2020. COVID-19 myocarditis: a case report.
33123774 2020. Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study.
33084959 2020. Micronutrients and bioactive compounds in the immunological pathways related to SARS-CoV-2 (adults and elderly).
33115675 2020. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
33031797 2020. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment.
33145015 2020. Bioinformatic study to discover natural molecules with activity against COVID-19.
33123349 2020. In vitro efficacy of a copper iodine complex PPE disinfectant for SARS-CoV-2 inactivation.
33082935 2020. Immunopathology of galectin-3: an increasingly promising target in COVID-19.
33038452 2020. Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic.
33133525 2020. Curcumin (a constituent of turmeric): New treatment option against COVID-19.
33102533 2020. QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment.
33195215 2020. Potential Use of Alpha-1 Anti-trypsin in the Covid-19 Treatment.
33123533 2020. Designing a Network Proximity-Based Drug Repurposing Strategy for COVID-19.
33102489 2020. Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis.
33101215 2020. Stabilizing Cellular Barriers: Raising the Shields Against COVID-19.
33101200 2020. Vitamin D and Sex Differences in COVID-19.
33042027 2020. Mediterranean Diet and COVID-19: Hypothesizing Potential Benefits in People With Diabetes.
33193695 2020. Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug Repositioning Through Virus-Drug Association Prediction.
33193684 2020. Predicting the Animal Susceptibility and Therapeutic Drugs to SARS-CoV-2 Based on Spike Glycoprotein Combined With ACE2.
33193639 2020. Underlying Mechanisms and Candidate Drugs for COVID-19 Based on the Connectivity Map Database.
33173539 2020. Identification of Novel SARS-CoV-2 Drug Targets by Host MicroRNAs and Transcription Factors Co-regulatory Interaction Network Analysis.
33195334 2020. IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections.
33195318 2020. Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
33195402 2020. Determine the Potential Epitope Based Peptide Vaccine Against Novel SARS-CoV-2 Targeting Structural Proteins Using Immunoinformatics Approaches.
33195397 2020. Drug Weaponry to Fight Against SARS-CoV-2.
33134311 2020. Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches.
33134310 2020. Discovery of Potential Flavonoid Inhibitors Against COVID-19 3CL Proteinase Based on Virtual Screening Strategy.
33132558 2020. Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.
33078736 2020. The narrow road to a COVID-19 vaccine.
33078733 2020. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
33075484 2020. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis.
33191178 2020. Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2.
33189613 2020. Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope.
33182059 2020. Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D.
33182040 2020. Lower levels of vitamin D are associated with SARS-CoV-2 infection and mortality in the Indian population: An observational study.
33166692 2020. LPD-12, a Promising Lipopeptide to Control COVID-19.
33152450 2020. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial.
33189891 2020. Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.
33166694 2020. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.
33164789 2020. Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.
33122096 2020. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study.
33075513 2020. Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in SyrSpend() SF PH4 (dry).
33075512 2020. Methylene blue inhibits replication of SARS-CoV-2 in vitro.
33045354 2020. Projected supportive effects of Pycnogenol() in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection.
33045350 2020. Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2.
33075384 2020. Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.
33035673 2020. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
33091154 2020. Vaccine design based on 16 epitopes of SARS-CoV-2 spike protein.
33106779 2020. Phase 3 Randomized Controlled Trials on Exclusion of Participants with Kidney Disease in COVID-19.
33129421 2020. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties.
33131609 2020. Human recombinant soluble ACE2 in severe COVID-19.
33163976 2020. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians.
33088576 2020. Critical reappraisal of remdesivir investigational trials in COVID-19.
33088574 2020. Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world.
33072335 2020. Role of micronutrients in the management of coronavirus disease 2019.
33037698 2020. Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID-19: A review.
33034398 2020. A role for quercetin in coronavirus disease 2019 (COVID-19).
33047412 2020. Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure.
33111431 2020. N-Terminomics for the Identification of In Vitro Substrates and Cleavage Site Specificity of the SARS-CoV-2 Main Protease.
33030073 2020. The benefits of Vitamin D in the COVID-19 pandemic: biochemical and immunological mechanisms.
33125298 2020. Role of vitamin D in pathogenesis and severity of COVID-19 infection.
33111980 2020. Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial.
33107628 2020. A case of COVID-19, with cytokine storm, treated by consecutive use of therapeutic plasma exchange followed by convalescent plasma transfusion: A case report.
33107607 2020. Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients' oxygen requirements.
33073355 2020. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
33113210 2020. Is there a role for childhood vaccination against COVID-19?
33025993 2020. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
32985017 2020. Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies.
32964551 2020. Aframomum melegueta secondary metabolites exhibit polypharmacology against SARS-CoV-2 drug targets: in vitro validation of furin inhibition.
33159391 2020. A pharmacology-based comprehensive review on medicinal plants and phytoactive constituents possibly effective in the management of COVID-19.
32892684 2020. Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors.
33077403 2020. Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
33050993 2020. Thalidomide Should Be Tested as a Therapeutic Option in COVID-19 Pneumonia.
33155515 2020. Saporin, a Polynucleotide-Adenosine Nucleosidase, May Be an Efficacious Therapeutic Agent for SARS-CoV-2 Infection.
33068341 2020. [Moxibustion therapy in prevention and treatment of coronavirus disease 2019 (COVID-19): construction and application of non-contact diagnosis and treatment mode].
33081907 2020. [Possibility of mesenchymal stem cell transplantation in the treatment of coronavirus disease 2019].
33081905 2020. [Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?]
32912403 2020. [A single arm clinical study of 86 patients with common type of coronavirus disease 2019 treated by integrated traditional Chinese and Western medicine: multicenter case observation from 7 designated hospitals in Henan Province].
32912400 2020. [Whole-process prevention and treatment model of traditional Chinese medicine for coronavirus disease 2019 epidemics].

33157066 2020. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG.
33174766 2020. SARS-CoV-2: Influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP)-metabolism and on severity of COVID-19.
33161152 2020. Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019.
33169088 2020. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.
32954790 2020. Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19.
33178779 2020. Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.
33136210 2020. Tetracycline and viruses: a possible treatment for COVID-19?
33093748 2020. Remdesivir for COVID-19.
33032673 2020. Mechanisms linking the human gut microbiome to prophylactic and treatment strategies for COVID-19.
33106765 2020. Ayurveda and Allopathic Therapeutic Strategies in Coronavirus Pandemic Treatment 2020.
33052305 2020. Challenges and future directions of potential natural products leads against 2019-nCoV outbreak.
33180190 2020. Steroid administration in the Covid-19 era; timing does matter!
33118012 2020. New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease.
33135047 2020. EFFECT oF STATIN THERAPY oN SARS-CoV-2 INFECTION-RELATED.
33033717 2020. Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses.
33117121 2020. Would Repurposing Minocycline Alleviate Neurologic Manifestations of COVID-19?
33195371 2020. Covid-19 Quarantine: Impact of Lifestyle Behaviors Changes on Endothelial Function and Possible Protective Effect of Beetroot Juice.
33195370 2020. Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese Patients.
33195363 2020. Potential Role of Vitamin B6 in Ameliorating the Severity of COVID-19 and Its Complications.
33102511 2020. Thrombosis and COVID-19: The Potential Role of Nutrition.
33072589 2020. Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia.
33101042 2020. The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience.
33101037 2020. The Important Role of Volatile Components From a Traditional Chinese Medicine Dayuan-Yin Against the COVID-19 Pandemic.
33101023 2020. Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19).
33071794 2020. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?
33071786 2020. Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome.
33071781 2020. Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study.
33071777 2020. Lian Hua Qing Wen Capsules, a Potent Epithelial Protector in Acute Lung Injury Model, Block Proapoptotic Communication Between Macrophages, and Alveolar Epithelial Cells.
33041830 2020. Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena.
33041827 2020. Systems Pharmacology and Verification of ShenFuHuang Formula in Zebrafish Model Reveal Multi-Scale Treatment Strategy for Septic Syndrome in COVID-19.
33041819 2020. The Potential of Antiviral Peptides as COVID-19 Therapeutics.
33041814 2020. Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.
33041797 2020. In Silico Prediction of Molecular Targets of Astragaloside IV for Alleviation of COVID-19 Hyperinflammation by Systems Network Pharmacology and Bioinformatic Gene Expression Analysis.
33192602 2020. Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin.
33178033 2020. Physical Exercise and the Renin Angiotensin System: Prospects in the COVID-19.
33135113 2020. Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study.
33171852 2020. Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection.
33158276 2020. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
33187101 2020. Exposome and Immunity Training: How Pathogen Exposure Order Influences Innate Immune Cell Lineage Commitment and Function.
33192207 2020. Designing of Nucleocapsid Protein Based Novel Multi-epitope Vaccine Against SARS-COV-2 Using Immunoinformatics Approach.
33120196 2020. Ebselen, a new candidate therapeutic against SARS-CoV-2.
33131033 2020. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience.
33063792 2020. Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy.
33196058 2020. Possible protective role of 17beta-estradiol against COVID-19.
33077329 2020. Nitric Oxide Ventilation Improves Recirculation and Right Ventricular Function During Veno-Venous Extracorporeal Membrane Oxygenation in a COVID-19 Patient.
33189533 2020. Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series.
33091590 2020. Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19.
33166894 2020. A preparative chiral separation of hydroxychloroquine using supercritical fluid chromatography.
33041506 2020. Evaluation of the nutritional status in patients with COVID-19.
33188624 2020. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
33029275 2020. Low-Flow Nasal Cannula Hydrogen Therapy.
33029269 2020. Could Estrogen Protect Women From COVID-19?
33099370 2020. Reissuing the sigma receptors for SARS-CoV-2.
33194123 2020. Back to basics: review on vitamin D and respiratory viral infections including COVID-19.
33103220 2020. Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein.
33034007 2020. Combining fragment docking with graph theory to improve ligand docking for homology model structures.
33038449 2020. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
33102263 2020. Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients.
33058941 2020. Do hydrogen peroxide mouthwashes have a virucidal effect? A systematic review.
33168456 2020. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
33109497 2020. Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone.
33054210 2020. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
33030607 2020. Intravenous immunoglobulin therapy in COVID-19-related encephalopathy.
33155635 2020. Letter to the Editor: Is Vitamin D One of the Key Elements in COVID-19 Days?
33155630 2020. Relation of Dietary Factors with Infection and Mortality Rates of COVID-19 across the World.
33109269 2020. Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework.
33182350 2020. Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?
33115823 2020. A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the COVID-19 Pandemic.
33095007 2020. Antiviral Peptides as Promising Therapeutics against SARS-CoV-2.
33104327 2020. COSMO-RS-Based Descriptors for the Machine Learning-Enabled Screening of Nucleotide Analogue Drugs against SARS-CoV-2.
33092337 2020. Immune response to physical exercise: evidence to take into account during the coronavirus disease (COVID-19) pandemic.
33162308 2020. Could Bronchial Artery Embolization Be a Modality for Treating Severe Acute Respiratory Syndrome Coronavirus 2?
33102950 2020. The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.
33163977 2020. Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.
32896291 2020. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
32896290 2020. COVID-19 vaccines: early success and remaining challenges.
32971041 2020. Safety and efficacy of the Russian COVID-19 vaccine: more information needed.
33172794 2020. Drug-induced QT prolongation in COVID-19 pneumonia: influence on in-hospital survival.
33179954 2020. Access considerations for a COVID-19 vaccine for South Africa.
33140636 2020. Toward COVID-19 Therapeutics: A Viewpoint from the Nonprotein Amino Acid Based Synthetic Peptide Design Approach.
33120507 2020. Response to Comment on Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection.
33120503 2020. Comment on Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles.
33177042 2020. Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients.
33104430 2020. Nutritional Care in Relation to COVID-19.
33112664 2020. Caution warranted for low-dose radiation therapy for Covid-19.
32915766 2020. Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood.
33090501 2020. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
33022386 2020. Curb complement to cure COVID-19.
33144402 2020. Rationale for the use of sphingosine analogues in COVID-19 patients.
33113246 2020. Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.
33085221 2020. Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States.
33135382 2020. A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.
33048372 2020. Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data.
32936948 2020. Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them.
32936947 2020. Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures (AGPs) on patients without suspected or confirmed COVID-19 infection.
33044747 2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
33148952 2020. Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information.
33031192 2020. Angiotensin II Administration in Patients with COVID-19 Shock.
33146028 2020. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis.
33023358 2020. Making a case for using gammadelta T cells against SARS-CoV-2.
33059567 2020. Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19.
33023445 2020. Epidemiological Situation and Efficacy of Dexamethasone for the treatment planning of COVID-19: A perspective review.
33073612 2020. Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes treating lymphocytopenia and cytokine storm syndrome: A treatment proposal for COVID-19 patients.
33143478 2020. Role of povidone iodine in ophthalmic clinical practice amidst COVID-19 pandemic.
33047989 2020. Could bacteriophages be the answer to the COVID-19 crisis?
33164589 2020. Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints.
33146561 2020. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.
33172313 2020. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
33144490 2020. Classical Drug Digitoxin Inhibits Influenza Cytokine Storm, With Implications for Covid-19 Therapy.
33154234 2020. Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.
33154232 2020. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
33084153 2020. A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.

33161397 2020. Is G-CSF Dangerous in COVID-19: Why Not Use GM-CSF?
33173601 2020. Preclinical Studies of Immunogenity, Protectivity, and Safety of the Combined Vector Vaccine for Prevention of the Middle East Respiratory Syndrome.
33072499 2020. Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening.
33116249 2020. Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
33110240 2020. Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets.
33041326 2020. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice.
33081436 2020. Role of vitamin C in critically ill patients with COVID-19: is it effective?
32837898 2020. The effects of N-acetyl cysteine on acute viral respiratory infections in humans: A rapid review.
32837896 2020. The effects of vitamin D on acute viral respiratory infections: A rapid review.
32837892 2020. Multivitamins for acute respiratory tract infections: a rapid review.
33111375 2020. SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.
33031060 2020. Efficacy and safety of tocilizumab in COVID-19 patients.
33101838 2020. Anti-inflammatory substances from onions could be an option for treatment of COVID-19-a hypothesis.
33121978 2020. Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.
33164793 2020. More Good News on Statins and COVID-19.
33041111 2020. SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
33168381 2020. Dexmedetomidine in COVID-19: probing promises with prudence!
33071096 2020. Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians.
33146236 2020. Cardiac glycosides and COVID-19: would it be a promising therapeutic approach?
33115684 2020. COVID-19, steroids and other immunomodulators: The jigsaw is not complete.
33096261 2020. Anti-infective therapy against SARS-CoV-2: some light at the end of the tunnel?
33096260 2020. Vaccines against COVID-19.
33059104 2020. Nutritional support for critically ill patients with COVID-19: New strategy for a new disease?
33173857 2020. A novel approach to spinal anaesthesia to avoid aerosol-generating procedures in a patient with COVID-19 presenting for laser prostate surgery.
33121927 2020. The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro.
33082858 2020. Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology.
33048300 2020. Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
33123616 2020. The role of nicotinic receptors in SARS-CoV-2 receptor ACE2 expression in intestinal epithelia.
33149560 2020. Targeting the GRP78-Dependant SARS-CoV-2 Cell Entry by Peptides and Small Molecules.
33031540 2020. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19.
33032282 2020. Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases.
33171470 2020. Hemoperfusion as a Potential Treatment for Critically Ill COVID-19 Patients with Cytokine Storm.
33176880 2020. Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M(Pro) inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
33093056 2020. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
33144278 2020. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
33173650 2020. Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series.
33089050 2020. Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report.
33125946 2020. Repurposing anticancer drugs for the management of COVID-19.
33194871 2020. Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid.
33123934 2020. Delayed hospital admission and high-dose corticosteroids potentially prolong SARS-CoV-2 RNA detection duration of patients with COVID-19.
33083917 2020. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study.
33168957 2020. Nutritional strategies for the rehabilitation of COVID-19 patients.
33051695 2020. Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies.
33163124 2020. Exploring the potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019 (COVID-19) through a combination of data mining and network pharmacology analysis.
33132004 2020. Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness.
33127218 2020. Does hydroxychloroquine reduce mortality for COVID-19?
33162299 2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.
33164596 2020. The risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case.
33057452 2020. Potential bioactive glycosylated flavonoids as SARS-CoV-2 main protease inhibitors: A molecular docking and simulation studies.
33057358 2020. Design of novel multiepitope constructs-based peptide vaccine against the structural S, N and M proteins of human COVID-19 using immunoinformatics analysis.
33031409 2020. Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia.
33027297 2020. BCG epidemiology supports its protection against COVID-19? A word of caution.
33119725 2020. "Trained immunity" from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes.
33137165 2020. The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors.
33119227 2020. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?
33119226 2020. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend? Authors' reply.
33183986 2020. A patient affected by critical COVID-19 pneumonia, successfully treated with convalescent plasma.
33162341 2020. Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy.
33153902 2020. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation.
33071174 2020. A case of COVID-19 Convalescent Plasma Donation in Greece: Directed donation for compassionate use in the donor's critically ill father.
33073202 2020. Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19.
33073200 2020. Heme/Hemeoxygenase-1 System Is a Potential Therapeutic Intervention for COVID-19 Patients with Severe Complications.
33073199 2020. Achilles' Heel of SARS-CoV-2 Structure.
33073198 2020. Therapeutically Targeted Destabilization of the Quaternary Structure of the Spike Protein in the Dominant G614 Strain of SARS-CoV-2.
33170176 2020. A pilot study on the preventative potential of alpha-cyclodextrin and hydroxytyrosol against SARS-CoV-2 transmission.
33170175 2020. Pilot study for the evaluation of safety profile of a potential inhibitor of SARS-CoV-2 endocytosis.
33170174 2020. Natural compounds as inhibitors of SARS-CoV-2 endocytosis: A promising approach against COVID-19.
33151168 2021. Sitagliptin: a potential drug for the treatment of COVID-19?
33151166 2021. Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies.
33148006 2020. Development of Rapid Advice Guidelines for the Treatment of Coronavirus Disease 2019 with Traditional Chinese Medicine.
33148005 2020. Traditional Chinese Medicine Formulation Therapy in the Treatment of Coronavirus Disease 2019 (COVID-19).
33136567 2020. Lopinavir-Ritonavir and Liver Involvement in Patients With COVID-19.
33105209 2020. Do Low Vitamin D Levels Increase COVID-19 Risk?
33085908 2020. COVID-19, Hypercoagulability and Cautiousness with Convalescent Plasma.
33093359 2020. Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19.
33049143 2020. Ethnic and Sex Representation in Trials Shaping Best Practice for Covid-19.
33166179 2020. Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial.
33093065 2020. Covid-19: Vaccine trials need more transparency to enable scrutiny and earn public trust, say experts.
33093025 2020. Convalescent plasma is ineffective for covid-19.
33093016 2020. Covid-19: Human challenge studies will see people purposefully infected with virus.
33087398 2020. Will covid-19 vaccines save lives? Current trials aren't designed to tell us.
33087395 2020. Covid-19 vaccine trial protocols released.
33077424 2020. Covid-19: Remdesivir has little or no impact on survival, WHO trial shows.
33130588 2020. Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection.
33038909 2020. Targeted delivery of CRISPR/Cas13 as a promising therapeutic approach to treat SARS-CoV-2.
33109039 2020. The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment.
33148151 2020. Insights from Pharmaceutical Biotechnology into Phenolic Biopharmaceuticals against COVID-19.
33176643 2020. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach Against COVID-19.
33176642 2020. Potential implications of black seed and its principal constituent Thymoquinone in the treatment of COVID-19 patients.
33023440 2020. Quinoline-based Compounds as Key Candidates to Tackle Drug Discovery Programs of Microbicidal Agents.
33100195 2020. COVID-19 Vaccines on Clinical Trials and their Mode of Action for Immunity against the Virus.
33059564 2020. The undiscovered potential of essential oils for treating SARS-CoV-2 (COVID- 19).
33155905 2020. Properties of Ethno-Medicinal Plants and Their Bioactives-Possible Use for Prevention and Treatment of COVID-19: A Review.
33155902 2020. Current landscape of natural products against coronaviruses: perspectives in COVID-19 treatment and antiviral mechanism.
33176644 2020. Are Hsp90 inhibitors good candidates against Covid-19?
33094291 2020. Luminespib counteracts the Kifunensine-induced lung endothelial barrier dysfunction.
33045970 2020. Stem Cell Therapy: A Promising Approach in Treatment of COVID 19.
33153418 2020. Most Promising Compounds for Treating COVID-19 and Recent Trends in Antimicrobial & Antifungal Agents.
33040729 2020. Importance of Environmental Factors on Production of Computationally- Defined Natural Molecules against COVID-19 Pandemic.
33030464 2020. What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks.
33107144 2020. COVID-19: Topical agents and therapeutic prevention of nasal viral acquisition.
33033068 2020. Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards.
33054486 2020. Deciphering Vaccines for COVID-19: where do we stand today?
33106053 2020. Biochemical and immunological aspects of COVID-19 infection and therapeutical intervention of oral low dose cytokine therapy: a systematic review.
33152797 2020. Rapid improvement of a critically ill obstetric patient with SARS-CoV-2 infection after administration of convalescent plasma.
33029911 2020. A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects.
33143519 2020. Adverse drug reactions associated with concurrent acute psychiatric treatment and Covid-19 drug therapy.
33121250 2020. The COVID-19 Pandemic and the Relevance of Ayurveda's Whole Systems Approach to Health and Disease Management.
33064060 2020. Magnesium and COVID-19 - Some Further Comments - A Commentary on Wallace TC. Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition? J Am Coll Nutr. 2020;1-9. doi:10.1080/07315724.2020.1785971. Cited in: PMID: 32649272.
33048028 2020. Does Serum Vitamin D Level Affect COVID-19 Infection and Its Severity?-A Case-Control Study.
33136164 2020. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
33087532 2020. Upcoming SARS-CoV-2 vaccine: expectations and reality.

33072869 2020. Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality.
33052316 2020. Use of oral antiseptics for SARS-CoV-2 infection.
33038588 2020. COVID-19 induced ARDS, and the use of galantamine to activate the cholinergic anti-inflammatory pathway.
33045596 2020. A possible application of hinokitiol as a natural zinc ionophore and anti-infective agent for the prevention and treatment of COVID-19 and viral infections.
33129578 2020. May interferon lambda be a novel therapeutic approach against COVID-19?
33129007 2020. Therapeutic potential for clomiphene, a selective estrogen receptor modulator, in the treatment of COVID-19.
33129009 2020. Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis.
33129008 2020. A multiple therapy hypothesis for treatment of COVID-19 patients.
33029105 2020. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors.
33048786 2020. Efectos adversos de lopinavir/ritonavir en enfermedad grave por coronavirus (COVID-19).
33048783 2020. Terapia con plasma de convalecientes en pacientes COVID-19 en la Provincia de Buenos Aires.
33194150 2020. "Hemolysis, or not Hemolysis, that is the Question". Use of Hydroxychloroquine in a Patient with COVID-19 Infection and G6PD Deficiency.
33196010 2020. Potential Role of Anti-Complement Agents in the Treatment of COVID-19-Related ARDS.
33196003 2020. Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?
33091582 2020. Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2.
33092045 2020. Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico.
33080900 2020. In silico Investigation on the Inhibiting Role of Nicotine/Caffeine by Blocking the S Protein of SARS-CoV-2 Versus ACE2 Receptor.
33172191 2020. New Technologies for Influenza Vaccines.
33167389 2020. Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases.
33064288 2020. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.
33079314 2020. Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors.
33065038 2020. Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines.
32911757 2020. Polyphenols vs. Coronaviruses: How Far Has Research Moved Forward?
33137605 2020. Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection?
33087898 2020. COVID-19 antibodies on trial.
33028832 2020. Many small steps towards a COVID-19 drug.
33087721 2020. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein.
33082342 2020. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.
33149112 2020. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.
33188207 2020. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
33090359 2020. Hordatines as a Potential Inhibitor of COVID-19 Main Protease and RNA Polymerase: An In-Silico Approach.
33057955 2020. The upshot of Polyphenolic compounds on immunity amid COVID-19 pandemic and other emerging communicable diseases: An appraisal.
33067570 2020. Learning from the past: development of safe and effective COVID-19 vaccines.
33082565 2020. HCQ use not protective against SARS-CoV-2.
33030660 2020. QTc interval prolongation, COVID-19 and chloroquine.
33042552 2020. Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review.
32983541 2020. First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2.
33106729 2020. A potential treatment for COVID-19 based on modal characteristics and dynamic responses analysis of 2019-nCoV.
33083549 2020. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19.
33088593 2020. Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2.
33083031 2020. Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein.
33083026 2020. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.
33134417 2020. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients.
33117850 2020. Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience.
33072814 2020. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia.
33085486 2020. Cyanoamidine Cyclization Approach to Remdesivir's Nucleobase.
33048168 2020. Sex-specific association between vitamin D deficiency and COVID-19 mortality in older patients.
33073552 2020. Repurposing of drugs for Covid-19: a systematic review and meta-analysis.
33089038 2020. Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.
33076482 2020. Sepsis, Phages, and COVID-19.
33050463 2020. Genomic Diversity and Hotspot Mutations in 30,983 SARS-CoV-2 Genomes: Moving Toward a Universal Vaccine for the "Confined Virus"?
33167401 2020. Antibody-Based Immunotherapeutic Strategies for COVID-19.
33182546 2020. SARS-CoV-2 Vaccines: Inactivation by Gamma Irradiation for T and B Cell Immunity.
33194450 2020. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review.
33080877 2020. Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.
33182811 2020. Role of 2-[(18)F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review.
33105618 2020. Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing.
33165762 2020. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients.
33113146 2020. Overview of the possible role of vitamin C in management of COVID-19.
33108587 2020. Favipiravir use for SARS CoV-2 infection.
33063271 2020. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.
33040252 2020. Observational study of people infected with SARS-Cov-2, treated with amantadine.
33096221 2020. Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro.
33124786 2020. Nucleotide analogues as inhibitors of SARS-CoV Polymerase.
33158717 2020. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.
33041173 2020. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2.
33067112 2020. Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic.
33000510 2020. Molecular and functional resemblance of dexamethasone and quercetin: A paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients.
32969524 2020. The natural way forward: Molecular dynamics simulation analysis of phytochemicals from Indian medicinal plants as potential inhibitors of SARS-CoV-2 targets.
32945590 2020. Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2).
33037564 2020. Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review.
33173705 2020. The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions.
33166303 2020. Monitor for COVID-19 vaccine resistance evolution during clinical trials.
33180803 2020. Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking.
33175880 2020. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.
33173052 2020. Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy.
33127296 2020. Transforming vaccine development.
33159214 2020. Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population.
33169564 2020. [Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review].
33169563 2020. [Mesenchymal stem cells in the treatment of COVID-19-progress and challenges].
32951007 2020. Targeting multiple epitopes on the spike protein: a new hope for COVID-19 antibody therapy.
33043784 2020. High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2.
33107685 2020. Severe Acute Respiratory Syndrome Coronavirus-2 Spike Protein Nanogel as a Pro-Antigen Strategy with Enhanced Protective Immune Responses.
33163859 2020. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.
33134845 2020. Antidiabetes Agents against Sars-Cov-2 Infection.
33043249 2020. Reactivation of SARS-CoV-2 after Asymptomatic Infection while on High-Dose Corticosteroids. Case Report.
33103063 2020. Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.
33103062 2020. Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guerin (BCG): Case Report.
33062267 2020. Convalescent plasma appears efficacious and safe in COVID-19.
33177829 2020. N-Acetylcysteine to Combat COVID-19: An Evidence Review.
33111176 2020. Patient Contribution to the Development and Safe Use of Medicines During the Covid-19 Pandemic.
33172237 2020. Vitamin D og covid-19.
33052306 2020. Comparative docking studies to understand the binding affinity of nicotine with soluble ACE2 (sACE2)-SARS-CoV-2 complex over sACE2.
33169107 2020. Synergy of melanin and vitamin-D may play a fundamental role in preventing SARS-CoV-2 infections and halt COVID-19 by inactivating furin protease.
33072871 2020. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest.
33153922 2020. Repurposing Antimalarials to Tackle the COVID-19 Pandemic.
33153921 2020. Potential Influence of Helminth Molecules on COVID-19 Pathology.
33027867 2020. COVID-19 death and BCG vaccination.
33169711 2020. The role of probiotics in COVID-19 treatment: Gut microbiota can help physicians in the outbreak.
33078604 2020. A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.
33177924 2020. The Effect of Therapeutic Plasma Exchange on COVID-19 Therapy.
33052520 2020. Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit.
33130382 2021. A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2.
33115670 2021. Ozone therapy in COVID-19: A narrative review.
33086123 2021. Nitric oxide (NO) and nanoparticles - Potential small tools for the war against COVID-19 and other human coronavirus infections.
33039544 2021. Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection.
33080984 2020. Identification and Tracking of Antiviral Drug Combinations.
33081350 2020. Viral Related Tools against SARS-CoV-2.
33072240 2020. Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions.
33083387 2020. Role of monoclonal antibody drugs in the treatment of COVID-19.
33033561 2020. Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19.
33178392 2020. Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome.

33138964 2020. Inhaled nitric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome.
33133323 2020. A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection.
33136431 2020. COVID-19 Basics and Vaccine Development with a Canadian Perspective.
33129484 2020. The importance of robust research methodology in the era of COVID-19 and beyond.
33043132 2020. Adjunct low level laser therapy (LLLT) in a morbidly obese patient with severe COVID-19 pneumonia: A case report.
33082891 2020. The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.
33058086 2020. Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study.
33083006 2020. Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation.
33152278 2020. Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics.
33137649 2020. Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19.
33040594 2020. Stem Cell Transplantation Therapy: A Potential Method for Treating Cytokine Storm Syndromes Induced by COVID-19.
33160536 2020. First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19.
33030653 2020. Clinical Practice Guidelines and Experts' Consensuses for Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Chinese Herbal Medicine: A Systematic Review.
33133232 2020. Anti-COVID-19 drug screening: Frontier concepts and core technologies.
33073222 2020. Rapid Response to Cytokine Storm Inhibition using Anakinra in a Patient with COVID-19 Myocarditis.
33042544 2020. Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series.
33116907 2020. Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?
33163696 2020. Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries.
33102933 2020. Is the shielding effect of cholecalciferol in SARS CoV-2 infection dependable? An evidence based unraveling.
32935331 2020. Vaccines for COVID-19.
33128197 2020. Emerging treatment strategies for COVID-19 infection.
33065237 2020. Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series.
33166647 2020. Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response.
33161150 2020. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
33055231 2020. Remdesivir against COVID-19 and Other Viral Diseases.
33033459 2020. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?
33097304 2020. Polydatin and its potential protective effect on COVID-19.
33162193 2020. Reply - Letter to the editor - Nutritional interventions to modulate haemoglobin-oxygen affinity in COVID-19 patients.
33168324 2020. Nutritional interventions to modulate haemoglobin-oxygen affinity in COVID-19 patients.
33088506 2020. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19).
33082954 2020. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study.
33135358 2020. Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID-19.
33135340 2020. Instantaneous "catch-and-kill" inactivation of SARS-CoV-2 by nitride ceramics.
33144317 2020. Key populations for early COVID-19 immunization: preliminary guidance for policy.
33174415 2020. Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease.
33175236 2020. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.
33174418 2020. Epitope-Based Potential Vaccine Candidate for Humoral and Cell-Mediated Immunity to Combat Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic.
33147968 2020. In Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2.
33173161 2020. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.
33063409 2020. Treatment of Stage 3 COVID-19 With Transcutaneous Auricular Vagus Nerve Stimulation Drastically Reduces Interleukin-6 Blood Levels: A Report on Two Cases.
33158787 2020. Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.
33158786 2020. Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?
33151329 2020. Hydrogen therapy as an effective and novel adjuvant treatment against COVID-19.
33151328 2020. Response to: Hydrogen therapy as an effective and novel adjuvant treatment against COVID-19.
33047045 2020. Targeting the glycan of receptor binding domain with jacalin as a novel approach to develop a treatment against COVID-19.
33065184 2020. Low dose radiation therapy for COVID-19: Effective dose and estimation of cancer risk.
33126054 2020. Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker.
33043232 2020. Thrombo-inflammation response to Tocilizumab in COVID-19.
33067149 2020. Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.
33190086 2020. Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.
33041391 2020. Coronaviruses and Nature's Pharmacy for the Relief of Coronavirus Disease 2019.
33053024 2020. Sindrome do desconforto respiratorio agudo associada a COVID-19 tratada com DEXametasona (CoDEX): delineamento e justificativa de um estudo randomizado.
33070542 2020. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection.
33070539 2020. Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19.
33077410 2020. Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.
33069612 2020. Main challenges of electrolyte imbalance in older patients with coronavirus disease and risk of QT prolongation. Response.
33120400 2020. Infusion of Convalescent Plasma is associated with Clinical Improvement in Critically Ill Patients With Covid-19: A Comment.
33077267 2020. Chez les sujets hospitalises pour COVID-19, est-ce que la dexamethasone diminue la mortalite a 28jours comparativement au traitement standard ?
33087414 2020. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.
33100032 2020. Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV.
33110386 2020. Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study.
33067239 2020. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design.
33158912 2020. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M(pro) and cathepsin L.
33187978 2020. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
33097472 2020. Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.
33036961 2020. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.
33163740 2020. Coronavirus Disease (COVID-19) and Africa: acclaimed home remedies.
33097791 2020. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone.
33082473 2020. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.
33077899 2020. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
33077836 2020. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
33077821 2020. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation.
33138949 2020. Letter to the editor: Covid-19 and Vit-D: Disease mortality negatively correlates with sunlight exposure.
33129692 2020. CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects.
33121422 2020. Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review.
33069201 2020. BCG vaccine, a ray of hope in treating Severe Acute Respiratory Syndrome (SARS).
33050869 2020. COVID-19 And Type 2 Diabetes Mellitus: Hydroxychloroquine May Be The Holy Grail.
33118690 2020. Prophylactic and therapeutic topical povidone-iodine in coronavirus disease 2019 (COVID-19): What is the evidence?
33063627 2020. ECCO2R with cytokine filtering in COVID-19 patients: Who wants to go down this road?
33141018 2020. COVID-19: Cytokine storm modulation/blockade with oral polyvalent immunoglobulins (PVIG, KMP01D): A potential and safe therapeutic agent (Primum nil nocere).
33156564 2020. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
33090785 2020. Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease.
33159440 2020. Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection.
33128482 2020. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
33098139 2020. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
33180360 2020. Treatment With Tocilizumab for Patients With COVID-19 Infections: A Case-Series Study.
33118617 2020. Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials.
33155686 2020. Defining IL-6 levels in healthy individuals: A meta-analysis.
33150961 2020. SARS-CoV-2 and inflammatory responses: from mechanisms to the potential therapeutic use of intravenous immunoglobulin.
33164959 2020. Navigating the ethical Scylla and Charybdis of the COVID vaccine.
33180938 2020. Update from the Advisory Committee on Immunization Practices.
33115235 2020. Hydroxychloroquine Exhibits a Strong Complex Interaction with DNA: Unraveling the Mechanism of Action.
33108677 2020. Melatonin controversies, an update.
33042589 2020. Pharmacological approaches to the treatment of COVID-19 patients.
33073873 2020. Can Low-Intensity Pulsed Ultrasound Treat Discrete Pulmonary Lesions in Patients With COVID-19?
33080017 2020. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
33080005 2020. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
33080002 2020. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
33079980 2020. Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia.
33094848 2020. Clinical Nutrition Research and the COVID-19 Pandemic: A Scoping Review of the ASPEN COVID-19 Task Force on Nutrition Research.
33131470 2020. [Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)].
33125934 2020. Who should be prioritised for COVID-19 vaccines?
33125914 2020. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
33035967 2020. COVID-19, myocardial edema and dexamethasone.
33151866 2020. COVID-19 et vaccination : une deregulation globale.
33080270 2020. Mediterranean diet as a nutritional approach for COVID-19.
33109047 2020. Perspectives for the use of N-acetylcysteine as a candidate drug to treat COVID-19.
33169027 2020. What Pfizer's landmark COVID vaccine results mean for the pandemic.
33177689 2020. Russia announces positive COVID-vaccine results from controversial trial.
33168970 2020. COVID vaccination logistics: five steps to take now.
33084621 2020. Bromelain: A Review on its Potential as a Therapy for the Management of Covid-19.
33039952 2020. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19).

33085408 2020. Remdesivir
33088671 2020. Targeting complement cascade: an alternative strategy for COVID-19.
33140033 2020. Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders.
33140032 2020. Fighting COVID-19 Using Molecular Dynamics Simulations.
33140031 2020. New Chemical Modalities Enabling Specific RNA Targeting and Degradation: Application to SARS-CoV-2 RNA.
33072646 2020. Necessity to Prioritize Research Activities for a Better Public Health Response to Coronavirus Disease-2019 Pandemic.
32864330 2020. The effects of Sambucus nigra berry on acute respiratory viral infections: A rapid review of clinical studies.
32837900 2020. The effects of Hedera helix on viral respiratory infections in humans: A rapid review.
33062600 2020. Angiotensin 1-7: A Novel Strategy in COVID-19 Treatment.
33173718 2020. Bioinspired DNase-I-Coated Melanin-Like Nanospheres for Modulation of Infection-Associated NETosis Dysregulation.
33173846 2020. Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2.
33108622 2020. Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.
33043128 2020. A Cyclodextrin-Stabilized Spermine-Tagged Drug Triplex that Targets Theophylline to the Lungs Selectively in Respiratory Emergency.
33173808 2020. Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector.
33173809 2020. Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.
33034016 2020. Prognostic role of nutritional status in elderly patients hospitalized for COVID-19: a monocentric study.
33044799 2020. Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19.
33029761 2020. Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections.
33094446 2020. Zinc and COVID-19: Basis of Current Clinical Trials.
33170448 2020. Trace Element Zinc, a Nature's Gift to Fight Unprecedented Global Pandemic COVID-19.
33078028 2020. Is a healthy microbiome responsible for lower mortality in COVID-19?
33116397 2020. Glycopeptides as Potential Interventions for COVID-19.
33130319 2020. Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm.
33152914 2020. CRISPR/Cas13: A potential therapeutic option of COVID-19.
33113418 2020. Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19.
33049583 2020. GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies.
33102585 2020. Phytochemicals from Selective Plants Have Promising Potential against SARS-CoV-2: Investigation and Corroboration through Molecular Docking, MD Simulations, and Quantum Computations.
33029513 2020. Alkaloids from Cryptolepis sanguinolenta as Potential Inhibitors of SARS-CoV-2 Viral Proteins: An In Silico Study.
33029499 2020. Convalescent Plasma: A Challenging Tool to Treat COVID-19 Patients-A Lesson from the Past and New Perspectives.
33152192 2020. [Cloroquina y sus derivados en el manejo de la COVID-19: una revision sistematica exploratoria].
33066343 2020. A Possible Path towards Rapid Development of Live-Attenuated SARS-CoV-2 Vaccines: Plunging into the Natural Pool.
33172012 2020. Fragment Library of Natural Products and Compound Databases for Drug Discovery.
33091672 2020. Nano-sized formazan analogues: Synthesis, structure elucidation, antimicrobial activity and docking study for COVID-19.
33160024 2020. Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2.
33135430 2020. CRISPR vs COVID-19: how can gene editing help beat a virus?
33087047 2020. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.
32933914 2020. Cytokine storm and use of anakinra in a patient with COVID-19.
33087452 2020. Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?
33122319 2020. Timely access to trial data in the context of a pandemic: the time is now.
33158571 2020. Methylene blue as an anti-COVID-19 mouthwash in dental practice.
33111169 2020. No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.
33143316 2020. Aprotinin Inhibits SARS-CoV-2 Replication.
33105869 2020. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
33129791 2020. "Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis".
33075378 2020. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
33065103 2020. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The ICON Study.
33127564 2020. Commentary on "Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy" by D.C. Mastellos et al.
33115645 2020. Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19".
33117530 2020. Cilastatin: a potential treatment strategy against COVID-19 that may decrease viral replication and protect from the cytokine storm.
33098998 2020. Rational for meta-analysis and randomized treatment: the COVID-19 example.
33096242 2020. Has the door closed on hydroxychloroquine for SARS-COV-2?
33068758 2020. Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine.
33094324 2020. Exploring lectin-glycan interactions to combat COVID-19: lessons acquired from other enveloped viruses.
33181328 2020. Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.
33047152 2020. Vaccine development in the SARS-CoV-2 pandemic: a balancing act on accuracy and speed.
33179911 2020. Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity.
33031488 2020. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.
33089306 2020. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.
33063117 2020. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
33161818 2020. The Circadian Clock and Viral Infections.
33118480 2020. Uncaria tomentosa (cat's claw): a promising herbal medicine against SARS-CoV-2/ACE-2 junction and SARS-CoV-2 spike protein based on molecular modeling.
33164664 2020. Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches.
33181454 2020. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
33058394 2020. SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.
33176176 2020. Early, low-dose, short-term methylprednisolone decreased the mortality in critical COVID-19 patients: A multicenter retrospective cohort study.
33104179 2020. Neutralizing Antibody Responses in COVID-19 Convalescent Sera.
33153629 2020. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
33113295 2020. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
33085857 2020. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
33067219 2020. Morphoproteomics Identifies the Vitamin D Receptor as a Potential Therapeutic Partner in Alveolar Pneumocytes for COVID-19 Infected Patients.
33075259 2020. In adults exposed to COVID-19, hydroxychloroquine did not reduce confirmed or probable COVID-19; trial stopped for futility.
33095083 2021. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.
33127663 2020. Response to 'Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study' by Moiseev et al.
33127662 2020. Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study.
33084021 2020. Hemoadsorption cartridge and coronavirus disease 2019 infections: A case report and brief literature review.
33136592 2020. Treatment of Cytokine Storm in COVID-19 Patients With Immunomodulatory Therapy.
33099890 2020. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?
33176395 2020. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
33094998 2020. Flexible Synthetic Carbohydrate Receptors as Inhibitors of Viral Attachment.
33073571 2020. Gold/Silver Hybrid Nanoparticles with Enduring Inhibition of Coronavirus Multiplication through Multisite Mechanisms.
33169410 2020. Can BCG vaccine protect against COVID-19 via trained immunity and tolerogenesis?
33166093 2020. Can immunological manipulation defeat SARS-CoV-2? Why G-CSF induced neutrophil expansion is worth a clinical trial: G-CSF treatment against COVID-19.
33023432 2020. Therapeutic Options for Treatment of COVID-19: A Review from Repur-posed Drugs to New Drug Targets.
33034297 2020. Povidone-iodine and carrageenan are candidates for SARS-CoV-2 infection control.
33174654 2020. Traditional Chinese Medicine as a complementary therapy in combat with COVID-19-A review of evidence-based research and clinical practice.
33179983 2020. Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19.
33164048 2020. Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers.
33036548 2020. Molecular modeling study of tectoquinone and acteoside from Tectona grandis linn: a new SARS-CoV-2 main protease inhibitor against COVID-19.
33030105 2020. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding.
33030102 2020. Finding potent inhibitors for COVID-19 main protease (M(pro)): an in silico approach using SARS-CoV-3CL protease inhibitors for combating CORONA.
33078675 2020. Potential therapeutic effect of turmeric contents against SARS-CoV-2 compared with experimental COVID-19 therapies: in silico study.
33047658 2020. Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2.
33140690 2020. DFT and docking studies of designed conjugates of noscapines & repurposing drugs: promising inhibitors of main protease of SARS-CoV-2 and falcipan-2.
33115586 2020. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
33086298 2020. An Old Method as an Aid on the Novel Coronavirus.
33164606 2020. COVID-19 during Pregnancy and Postpartum.
33171544 2020. Food-derived antioxidants and COVID-19.
33064152 2020. Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
33064145 2020. Answering Key Questions About COVID-19 Vaccines.
33064144 2020. Postlicensure Evaluation of COVID-19 Vaccines.
33165621 2020. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
33180097 2020. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
33085870 2020. Audio Interview: Tocilizumab and Covid-19.
33053301 2020. Audio Interview: Vaccinology and Covid-19.
33028965 2020. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters.
33121282 2020. Potential of Ficus microcarpa metabolites against SARS-CoV-2 main protease supported by docking studies.
32719377 2020. mRNA vaccines: intellectual property landscape.
33045718 2020. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
33082543 2020. How obesity could create problems for a COVID vaccine.
33082537 2020. COVID-19 vaccines: time to talk about the uncertainties.
33077943 2020. All eyes on a hurdle race for a SARS-CoV-2 vaccine.
33057226 2020. How anti-ageing drugs could boost COVID vaccines in older people.

33067179 2020. Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19.
33055099 2020. Covid-19: Eli Lilly pauses antibody trial for safety reasons.
33051241 2020. Covid-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant.
33168564 2020. Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?
33168562 2020. Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate.
33153979 2020. Covid-19: NHS hospitals are urged to recruit more patients to Recovery trial to find what treatments work.
33125791 2020. Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women.
33119136 2020. Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs.
33085781 2020. Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis.
33164544 2020. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
6135 1976. Purine catabolism in man: characterization of placental microsomal 5'-nucleotidase.
33040779 2020. Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length.
33140889 2020. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19.
33031500 2020. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19.
33165503 2020. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.
33159196 2020. Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic.
33158957 2020. Preventing vitamin D deficiency during the COVID-19 pandemic: UK definitions of vitamin D sufficiency and recommended supplement dose are set too low.
33135607 2020. Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation.
33106140 2020. Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.
33155887 2020. A Computational Approach for Identifying Potential Phytochemicals Against Non-structural Protein 1 (Nsp1) of SARS-CoV-2.
33172372 2020. Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain.
33109057 2020. Molecular Docking Studies of Bioactive Nicotiflorin against 6W63 Novel Coronavirus 2019 (COVID-19).
33093279 2020. Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study.
33109061 2020. COVID-19 Infection and Vitamin D: Current Scenario and Future Prospects.
33109030 2020. COVID-19: innovative antiviral drugs required for long-term prevention and control of coronavirus diseases.
33109028 2020. Natural Products in Mitigation of SARS CoV Infections.
33109027 2020. Recent Advances towards Drug Design Targeting the Protease of 2019 novel coronavirus (2019-nCoV).
33109026 2020. COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed.
33106134 2020. Evidence and the main adverse effects regarding drug therapies in the war against COVID-19.
33143619 2020. Rediscovery of caffeine: an excellent drug for improving patient outcomes while fighting WARS.
32941186 2020. Obesity, vitamin D deficiency and old age a serious combination with respect to coronavirus disease-2019 severity and outcome.
33100248 2020. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.
32893468 2020. Efforts towards a COVID-19 vaccine.
33044166 2020. Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.
33047822 2020. Imposed mutational meltdown as an antiviral strategy.

33067179 2020. Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19.
33055099 2020. Covid-19: Eli Lilly pauses antibody trial for safety reasons.
33051241 2020. Covid-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant.
33168564 2020. Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?
33168562 2020. Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate.
33153979 2020. Covid-19: NHS hospitals are urged to recruit more patients to Recovery trial to find what treatments work.
33125791 2020. Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women.
33119136 2020. Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs.
33085781 2020. Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis.
33164544 2020. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
6135 1976. Purine catabolism in man: characterization of placental microsomal 5'-nucleotidase.
33040779 2020. Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length.
33140889 2020. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19.
33031500 2020. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19.
33165503 2020. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.
33159196 2020. Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic.
33158957 2020. Preventing vitamin D deficiency during the COVID-19 pandemic: UK definitions of vitamin D sufficiency and recommended supplement dose are set too low.
33135607 2020. Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation.
33106140 2020. Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.
33155887 2020. A Computational Approach for Identifying Potential Phytochemicals Against Non-structural Protein 1 (Nsp1) of SARS-CoV-2.
33172372 2020. Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain.
33109057 2020. Molecular Docking Studies of Bioactive Nicotiflorin against 6W63 Novel Coronavirus 2019 (COVID-19).
33093279 2020. Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study.
33109061 2020. COVID-19 Infection and Vitamin D: Current Scenario and Future Prospects.
33109030 2020. COVID-19: innovative antiviral drugs required for long-term prevention and control of coronavirus diseases.
33109028 2020. Natural Products in Mitigation of SARS CoV Infections.
33109027 2020. Recent Advances towards Drug Design Targeting the Protease of 2019 novel coronavirus (2019-nCoV).
33109026 2020. COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed.
33106134 2020. Evidence and the main adverse effects regarding drug therapies in the war against COVID-19.
33143619 2020. Rediscovery of caffeine: an excellent drug for improving patient outcomes while fighting WARS.
32941186 2020. Obesity, vitamin D deficiency and old age a serious combination with respect to coronavirus disease-2019 severity and outcome.
33100248 2020. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.
32893468 2020. Efforts towards a COVID-19 vaccine.
33044166 2020. Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.
33047822 2020. Imposed mutational meltdown as an antiviral strategy.

33150525 2020. Rescue therapy with inhaled nitric oxide and almitrine in COVID-19 patients with severe acute respiratory distress syndrome.
33090877 2020. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.
33074704 2020. COVID-19 Vaccine: What Physicians Need to Know.
33085507 2020. Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
32950986 2020. Switching Host Metabolism as an Approach to Dampen SARS-CoV-2 Infection.
33007381 2020. Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19.
32954754 2020. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study.
32921099 2020. Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials.
33050459 2020. May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?
33091434 2020. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
33173252 2020. Titanium (IV) complexes of some tetra-dentate symmetrical bis-Schiff bases of 1,6-hexanediamine: Synthesis, characterization, and in silico prediction of potential inhibitor against coronavirus (SARS-CoV-2).
33134963 2020. Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review.
33160751 2020. Role of Systemic and Nasal Glucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with SARS-Cov-2 Infection.
33168195 2020. GK1: An Alternative Treatment to Control the Respiratory Complications During COVID19.
33047848 2020. Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.
33177651 2020. Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection.
33181114 2020. In silico analysis of selected alkaloids against main protease (M(pro)) of SARS-CoV-2.
33031623 2020. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
33104777 2020. Avifavir in Treating Patients with Moderate Covid 19.
33103195 2020. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19.
33079180 2020. Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab.
33075124 2020. Favipiravir as an antiviral agent in COVID-19: same script, different cast?
33068425 2020. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial.
33053155 2020. Survival analysis of treatment efficacy in comparative COVID-19 studies.
33038227 2020. Convalescent plasma for patients with severe COVID-19: a matched cohort study.
33103512 2020. The probiotic Bifidobacterium in the management of Coronavirus: A theoretical basis.
33045858 2020. Cationic drugs and COVID-19.
33130197 2020. The art of the possible in approaching efficacy trials for COVID19 convalescent plasma.
33130203 2020. Role of favipiravir in the treatment of COVID-19.
33130195 2020. Why we should be more careful using hydroxychloroquine in influenza season?
33129966 2020. Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?
33127507 2020. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
33115682 2020. Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia.
33100779 2020. A prospective clinical study of an Ayurveda regimen in COVID 19 patients.
33071521 2020. Outcomes of Ayurvedic care in a COVID-19 patient with hypoxia - A Case Report.
33094891 2020. Discovery of novel pyrazole derivatives as a potent anti-inflammatory agent in RAW264.7 cells via inhibition of NF-kB for possible benefit against SARS-CoV-2.
33184246 2020. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
33167413 2020. Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines.
33089717 2020. Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2.
33041320 2020. Research on drugs and vaccines for COVID-19 should be conducted and published with caution.
33178638 2020. Physical exercise for strengthening innate immunity during COVID-19 pandemic: 4th series of scientific evidence.
33064151 2020. SARS-CoV-2 vaccine development, access, and equity.
32944185 2020. Systematic review of extracellular vesicle-based treatments for lung injury: are EVs a potential therapy for COVID-19?
33129444 2020. In Pursuit of a SARS-CoV-2 Vaccine.
33141358 2020. A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods.
33075521 2020. Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.
33065330 2020. Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection.
33134398 2020. Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
33062720 2020. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.
33115658 2020. Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19.
33031085 2020. Nitazoxanide against COVID-19 in three explorative scenarios.
33175709 2020. Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient.
33069626 2020. Effects of Tanreqing Capsule on the negative conversion time of nucleic acid in patients with COVID-19: A retrospective cohort study.
33060041 2020. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.
33054978 2020. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.
33071354 2020. Fenoterol and dobutamine as COVID-19 main protease inhibitors: A virtual screening study.
33148446 2020. Vitamin D Clinical Pharmacology: Relevance to COVID-19 Pathogenesis.
33088307 2020. Bioinformatics analysis of Wuhan novel coronavirus pathogen: A clue for finding antiviral drug against Wuhan novel coronavirus.
33065275 2020. Vitamin D and survival in COVID-19 patients: A quasi-experimental study.
33169114 2020. Why will it never be known if convalescent plasma is effective for COVID-19.
33062586 2020. Corticosteroids: A Controversial Therapy for Coronavirus Disease 2019.
33087150 2020. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
33059719 2020. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals.
33068703 2021. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
32971042 2020. What can we expect from first-generation COVID-19 vaccines?
33065034 2020. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
33069282 2020. A promising inactivated whole-virion SARS-CoV-2 vaccine.
33069281 2020. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
32979327 2020. The arrival of Sputnik V.
33121991 2020. Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.
33131749 2020. Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice.
33049279 2020. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics.
33189817 2020. The nucleocapsid protein of zoonotic betacoronaviruses is an attractive target for antiviral drug discovery.
33035581 2020. Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
33153626 2020. Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors.
33163895 2020. The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
33082259 2020. Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.
33067179 2020. Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19.
33055099 2020. Covid-19: Eli Lilly pauses antibody trial for safety reasons.
33051241 2020. Covid-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant.
33168564 2020. Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?
33168562 2020. Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate.
33153979 2020. Covid-19: NHS hospitals are urged to recruit more patients to Recovery trial to find what treatments work.
33125791 2020. Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women.
33119136 2020. Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs.
33085781 2020. Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis.
33164544 2020. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
6135 1976. Purine catabolism in man: characterization of placental microsomal 5'-nucleotidase.
33040779 2020. Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length.
33140889 2020. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19.
33031500 2020. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19.
33165503 2020. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.
33159196 2020. Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic.
33158957 2020. Preventing vitamin D deficiency during the COVID-19 pandemic: UK definitions of vitamin D sufficiency and recommended supplement dose are set too low.
33135607 2020. Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation.
33106140 2020. Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.
33155887 2020. A Computational Approach for Identifying Potential Phytochemicals Against Non-structural Protein 1 (Nsp1) of SARS-CoV-2.
33172372 2020. Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain.
33109057 2020. Molecular Docking Studies of Bioactive Nicotiflorin against 6W63 Novel Coronavirus 2019 (COVID-19).
33093279 2020. Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study.
33109061 2020. COVID-19 Infection and Vitamin D: Current Scenario and Future Prospects.
33109030 2020. COVID-19: innovative antiviral drugs required for long-term prevention and control of coronavirus diseases.
33109028 2020. Natural Products in Mitigation of SARS CoV Infections.
33109027 2020. Recent Advances towards Drug Design Targeting the Protease of 2019 novel coronavirus (2019-nCoV).
33109026 2020. COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed.
33106134 2020. Evidence and the main adverse effects regarding drug therapies in the war against COVID-19.
33143619 2020. Rediscovery of caffeine: an excellent drug for improving patient outcomes while fighting WARS.
32941186 2020. Obesity, vitamin D deficiency and old age a serious combination with respect to coronavirus disease-2019 severity and outcome.
33100248 2020. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.
32893468 2020. Efforts towards a COVID-19 vaccine.
33044166 2020. Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.
33047822 2020. Imposed mutational meltdown as an antiviral strategy.

33078087 2020. Vitamin D Update.
33125628 2020. Medical Nutrition Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection in a Non-critical Care Setting: Knowledge in Progress.
33128927 2020. Probable positive effects of the photobiomodulation as an adjunctive treatment in COVID-19: A systematic review.
33098610 2020. CD147 inhibitors as a treatment for melanoma: Promising agents against SARS-CoV-2 infection.
33032231 2020. Ivermectin in COVID-19: What do we know?
33120281 2020. Statins and SARS-CoV-2 disease: Current concepts and possible benefits.
33113472 2020. An update on the global vaccine development for coronavirus.
33052538 2020. Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions.
33052537 2020. A Response To: Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions.
33133998 2020. COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report.
33043284 2020. Sarilumab use in severe SARS-CoV-2 pneumonia.
33173853 2020. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study.
33078138 2020. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).
33043052 2020. Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space.
33117441 2020. Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice.
33117437 2020. Testosterone in COVID-19 - Foe, Friend or Fatal Victim?
33183404 2020. Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.
33123207 2020. Screening for Anti-Influenza Actives of Prefractionated Traditional Chinese Medicines.
33101440 2020. Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons.
33029165 2020. Investigating Potential Inhibitory Effect of Uncaria tomentosa (Cat's Claw) against the Main Protease 3CL(pro) of SARS-CoV-2 by Molecular Modeling.
33088255 2020. Vitamin D supplementation in COVID-19: A friend or foe?
33158784 2020. Evidence-based assessment of potential therapeutic effects of adjunct osteopathic medicine for multidisciplinary care of acute and convalescent COVID-19 patients.
33046408 2020. Do saline water gargling and nasal irrigation confer protection against COVID-19?
33091573 2020. Heme oxygenase-1 modulation: A potential therapeutic target for COVID-19 and associated complications.
33102461 2020. Co-aerosolized Pulmonary Surfactant and Ambroxol for COVID-19 ARDS Intervention: What Are We Waiting for?
33194800 2020. Systems Biology Approaches for Therapeutics Development Against COVID-19.
33195080 2020. Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations.
33195060 2020. Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain.
33123544 2020. Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.
33072783 2020. Covid-19 Pandemic: Maximizing Future Vaccination Treatments Considering Aging and Frailty.
33072781 2020. The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak.
33072773 2020. Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.
33043030 2020. Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences.
33192523 2020. Role of Traditional Chinese Medicine in the Management of Viral Pneumonia.
33192506 2020. Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements.
33192504 2020. Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of Glycyrrhiza glabra L. (Licorice).
33192503 2020. Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19.
33178026 2020. Current Prevention of COVID-19: Natural Products and Herbal Medicine.
33178016 2020. COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management.
33178011 2020. Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients.
33162891 2020. Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity-Opportunity for Repurposed Chemotherapy of COVID-19 Infection.
33162887 2020. Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease.
33154723 2020. Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis.
33132915 2020. Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients.
33132913 2020. "Fei Yan No. 1" as a Combined Treatment for COVID-19: An Efficacy and Potential Mechanistic Study.
33123014 2020. Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines.
32974268 2020. Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs.
32903641 2020. Convalescent Plasma: A Potential Life-Saving Therapy for Coronavirus Disease 2019 (COVID-19).
33187757 2020. What it will take to equitably distribute a COVID-19 vaccine.
33105142 2020. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
33062058 2020. How to boost the immune defence prior to respiratory virus infections with the special focus on coronavirus infections.
33041058 2020. Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report.
33163683 2020. Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins.
33062945 2020. SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma.
33156739 2020. Recent advances in vaccine and immunotherapy for COVID-19.
32900407 2020. Antimicrobial stewardship programs and convalescent plasma for COVID-19: A new paradigm for preauthorization?
32938504 2020. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.
33116688 2020. Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19.
33061471 2020. Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?
33130005 2020. A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.
33132111 2020. Overlapping host pathways between SARS-CoV-2 and its potential copathogens: An in silico analysis.
33102688 2020. In silico identification of drug candidates against COVID-19.
33102687 2020. Applying computer simulations in battling with COVID-19, using pre-analyzed molecular and chemical data to face the pandemic.
33052313 2020. Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools.
33043110 2020. Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19.
33169118 2020. Recovery of Four COVID-19 Patients via Ozonated Autohemotherapy.
33160854 2020. Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy.
33045577 2020. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.
33162345 2020. Application value of artificial liver support system in the treatment of cytokine storm in patients with COVID-19.
33129099 2020. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients.
33091817 2020. Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.
33075713 2020. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.
33080267 2020. Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.
33165417 2020. Network pharmacology-based study of the molecular mechanisms of Qixuekang in treating COVID-19 during the recovery period.
33113270 2020. Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease.
33113232 2020. Generalized exanthema due to hydroxychloroquine as a popular drug during COVID-19 prophylaxis.
33108703 2020. Can Tenofovir diphosphate be a candidate drug for Sars-Cov2? First clinical perspective.
33064918 2020. COVID-19 infection threat in patients with high-risk non-muscle invasive bladder cancer receiving intravesical BCG therapy.
33063447 2020. QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study.
33115677 2020. HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes.
33075525 2020. Hydroxychloroquine safety outcome with an approved therapeutic protocol for COVID-19 outpatients in Saudi Arabia.
33075529 2020. The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment?
33160064 2020. Arginine Depletion as a Therapeutic Approach for Patients with COVID-19.
33157292 2020. Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.
33157287 2020. Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19-An exploratory study.
33186704 2020. CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-Cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14.
33173434 2020. Herbal plants coordinate COVID-19 in multiple dimensions - An insight analysis for clinically applied remedies.
33029094 2020. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology.
33156381 2020. Impact of late administration of corticosteroids in COVID-19 ARDS.
33068241 2020. Remdesivir and COVID-19.
33150537 2020. The mental health and well-being benefits of exercise during the COVID-19 pandemic: a cross-sectional study of medical students and newly qualified doctors in the UK.
33083317 2020. Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis.
33070984 2020. Mitigating the transmission of infection and death due to SARS-CoV-2 through non-pharmaceutical interventions and repurposing drugs.
33043282 2020. Furin: A Potential Therapeutic Target for COVID-19.
33134887 2020. Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk.
33103068 2020. Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal.
33010257 2020. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study.
33040416 2020. Plasma exchange therapy and COVID-19.
33045077 2020. Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
33128490 2020. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis.
33148157 2020. Can Nutrition Play a Role as a Stimulant for COVID 19 in Children?
33077678 2020. Prospects for a safe COVID-19 vaccine.
33037066 2020. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
32972994 2020. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
33053601 2020. Early phase dose-finding trials in virology.
33165216 2020. Development and validation of a simple and rapid UHPLC-MS/MS method for the quantification of hydroxychloroquine in plasma and blood samples in the emergency context of SARS-CoV-2 pandemic.
33073895 2020. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients.
33125158 2020. Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2.
33104267 2020. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
32931666 2020. Hyperbaric oxygen therapy for COVID-19 patients with respiratory distress: treated cases versus propensity-matched controls.
32894904 2020. [Immune imbalance and immunoregulatory treatment of COVID-19].
33137863 2020. [Potential therapeutic drugs for novel coronavirus pneumonia].

33078035 2020. Modeling of the adsorption of a protein-fragment on kaolinite with potential antiviral activity.
33072222 2020. Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein.
33107132 2020. Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs.
33107123 2020. First case of COVID-19 infused with hESC derived immunity- and matrix-regulatory cells.
33098357 2020. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis.
33027617 2020. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain.
33163980 2020. Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells.
33031791 2020. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.
33121920 2020. Race to arsenal COVID-19 therapeutics: Current alarming status and future directions.
33098839 2020. System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.
33052144 2020. Identification of potential inhibitors of SARS-CoV-2 papain-like protease from tropane alkaloids from Schizanthus porrigens: A molecular docking study.
33041350 2020. Neuroprotective immunity by essential nutrient "Choline" for the prevention of SARS CoV2 infections: An in silico study by molecular dynamics approach.
33029193 2020. Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy.
33101604 2020. Side chain similarity comparisons for integrated drug repositioning and potential toxicity assessments in epidemic response scenarios: The case for COVID-19.
33102987 2020. Xanthene based hybrid analogues to inhibit protease of novel corona Virus: Molecular docking and ADMET studies.
33045402 2020. The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design.
33043163 2020. Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven.
33036833 2020. Theoretical novel COVID-19 vaccination risk of rare and severe adverse events versus COVID-19 mortality.
33096485 2020. Blockade of an innate immune amplifier to fight immune hyperactivation in COVID-19?
33038768 2020. Tocilizumab is recommended for the treatment of severe COVID-19.
33048175 2020. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.
33188451 2020. Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients.
33090434 2020. Could dantrolene be explored as a repurposed drug to treat COVID-19 patients by restoring intracellular calcium homeostasis?
33090432 2020. A critical appraisal of evidence in the use of preprocedural mouthwash to avoid SARS-CoV-2 transmission during oral interventions.
33195565 2020. Phytogenic Products and Phytochemicals as a Candidate Strategy to Improve Tolerance to Coronavirus.
33083627 2020. Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment.
33033884 2020. Umbilical cord: an allogenic tissue for potential treatment of COVID-19.
33046268 2020. Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E.
33166584 2020. Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19.
33100674 2020. Therapeutic status of hydroxychloroquine in COVID-19: A review.
33134212 2020. A New Look at the LDRT treatment for COVID-19 Associated Pneumonia: The Issues of Antiviral Resistance and Virus Spread-Ability.
33122473 2020. Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification.
33111624 2020. Deciphering underlying mechanism of Sars-CoV-2 infection in humans and revealing the therapeutic potential of bioactive constituents from Nigella sativa to combat COVID19: in-silico study.
33111622 2020. In silico analysis of the interactions of certain flavonoids with the receptor-binding domain of 2019 novel coronavirus and cellular proteases and their pharmacokinetic properties.
33111618 2020. Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-alpha with in-vitro effective drug ivermectin.
33107812 2020. Secondary metabolites from spice and herbs as potential multitarget inhibitors of SARS-CoV-2 proteins.
33103616 2020. Natural phyto, compounds as possible noncovalent inhibitors against SARS-CoV2 protease: computational approach.
33103586 2020. High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein.
33179586 2020. Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study.
33179568 2020. In-silico drug repurposing for targeting SARS-CoV-2 main protease (M(pro)).
33172342 2020. Nanobodies: an unexplored opportunity to combat COVID-19.
33140086 2020. Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents.
33073845 2020. BCG as an adjunct or alternative vaccine to prevent COVID-19?
33031764 2020. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
33031761 2020. Antiviral monotherapy for hospitalised patients with COVID-19 is not enough.
33091364 2020. Use of adenovirus type-5 vectored vaccines: a cautionary tale.
33010835 2020. Remdesivir and COVID-19 - Authors' reply.
33010833 2020. Remdesivir and COVID-19.
33010832 2020. Remdesivir and COVID-19.
33010831 2020. Remdesivir and COVID-19.
33010830 2020. Remdesivir and COVID-19.
33010825 2020. Leveraging the advances in HIV for COVID-19.
33078096 2020. Molecular Docking and ADMET Study of Bioactive Compounds of Glycyrrhiza glabra Against Main Protease of SARS-CoV2.
33037683 2020. The COVID-19 era and pediatric procedural sedation: A consecutive case series with an emphasis on preparation, precautions, and risk reduction.
33163186 2020. Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID-19.
33051923 2020. Attenuating COVID-19 infection and inflammation: Lessons from asthma.
33069616 2020. Calcineurin Inhibitors and COVID-19.
33138947 2020. Covid-19 and vit-d: Disease mortality negatively correlates with sunlight exposure.
33120121 2020. DFT calculations towards the geometry optimization, electronic structure, infrared spectroscopy and UV-vis analyses of Favipiravir adsorption on the first-row transition metals doped fullerenes; a new strategy for COVID-19 therapy.
33110915 2020. Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report.
33059757 2020. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
33089452 2020. Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein.
33161559 2020. Nanoconjugates-Based Stem Cell Therapy for the Management of COVID-19.
33188579 2020. Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection.
33106741 2020. Discovery of small molecule PLpro inhibitor against COVID-19 using structure-based virtual screening, molecular dynamics simulation, and molecular mechanics/Generalized Born surface area (MM/GBSA) calculation.
33152262 2020. Malleability of the SARS-CoV-2 3CL M(pro) Active-Site Cavity Facilitates Binding of Clinical Antivirals.
33099554 2020. SARS-CoV-2 in Semen.
33070138 2020. Semen Does Not Cause Additional Risk for SARS-CoV-2 Transmission during Sexual Contact.
33039209 2020. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
33139139 2020. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.
33097312 2020. Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.
33082015 2020. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
33071000 2020. Bacillus Calmette-Guerin (BCG) vaccine generates immunoregulatory cells in the cervical lymph nodes in guinea pigs injected intra dermally.
33069443 2020. COVID-19 vaccine trials: Duty of care and standard of prevention considerations.
33081331 2020. The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air.
33153096 2020. COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response.
33127010 2020. Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations.
33127008 2020. The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19).
33100613 2020. Molecular docking analysis of selected phytochemicals against SARS-CoV-2 M(pro) receptor.
33097047 2020. Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series.
33154979 2020. Baseline results of a living systematic review for COVID-19 clinical trial registrations.
33117894 2020. Baseline results of a living systematic review for COVID-19 funded research projects.
33164550 2020. Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment Through Hypothesis-Driven Systems Medicine Using CoVex.
33037029 2020. Covid-19: Experts advise cautious optimism for neutralising antibodies after early results.
33032983 2020. Covid-19: FDA defies Trump to publish rigorous vaccine development guidelines.
33023934 2020. Covid-19 elimination: consider population level effects of vaccine.
33086342 2020. Understanding COVID-19 Vaccines and Their Development.
33080582 2020. Nitric oxide's physiologic effects and potential as a therapeutic agent against Covid-19.
33055254 2020. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells.
33173010 2020. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
32579163 2020. Missed Opportunities on Emergency Remdesivir Use.
33160452 2020. Emergency use authorisation for COVID-19 vaccines: lessons from Ebola.
33159850 2020. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination.
33125926 2020. Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.
33113304 2020. Audio Interview: A New Monoclonal Antibody for Covid-19.
33093684 2020. SARS-CoV-2 M(pro) inhibitors and activity-based probes for patient-sample imaging.
33082574 2020. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
33140777 2020. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.
33167083 2020. Immunoprotective potential of Ayurvedic herb Kalmegh (Andrographis paniculata) against respiratory viral infections - LC-MS/MS and network pharmacology analysis.
33002827 2020. Rhamnocitrin extracted from Nervilia fordii inhibited vascular endothelial activation via miR-185/STIM-1/SOCE/NFATc3.
32902005 2020. Glycyrrhizin: An old weapon against a novel coronavirus.
32996197 2020. Arenaria kansuensis attenuates pulmonary fibrosis in mice via the activation of Nrf2 pathway and the inhibition of NF-kB/TGF-beta1/Smad2/3 pathway.
33051297 2020. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
33172366 2020. The PentaFOLD 3.0 algorithm for the selection of stable elements of secondary structure to be included in vaccine peptides.
33115218 2020. The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guerin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature.
33033203 2020. Inhibiting Ebola virus and SARS-CoV-2 entry.
33033196 2020. A call to test new vaccines head to head, in monkeys.
33154108 2020. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.
33154107 2020. De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2.
33154106 2020. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.
33087460 2020. Understanding COVID-19 vaccine efficacy.
33164326 2020. Advancements in protein nanoparticle vaccine platforms to combat infectious disease.